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ABSTRACT 
Hepatitis C virus (HCV) causes hepatitis C, a chronic liver condition that represents a 
global health burden with no optimal therapeutic agents and no vaccine available. 
Recent findings suggest that, apart from infecting hepatocytes directly, HCV can be 
transmitted from B-lymphocytes to hepatocytes in a process called trans-infection. 
This project characterises trans-infection further by examining the receptors and cell 
components involved in HCV transmission from B- and T-lymphocyte cell lines to 
hepatoma cells. Our results suggest both lymphocyte classes are equally capable of 
trans-infection, which can be significantly reduced in the presence of HCV entry 
receptor inhibitors or HCV-specific neutralising antibodies. The actin cytoskeleton of 
the target hepatocyte is also involved, although seemingly not through uptake of 
either live or dead lymphocytes. Further work is needed to fully characterise 
lymphocyte-mediated HCV infection of liver cells. This would provide us with crucial 
new insights into the varied modes of HCV transmission, with a view to designing 
more effective therapeutic approaches in the future. 
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1. INTRODUCTION 
Hepatitis C virus (HCV) is the cause of multiple chronic liver-associated pathologies 
with a huge impact on the sufferers’ quality of life on a global scale. Current antiviral 
treatments are suboptimal, and there is no vaccine yet that could confer protection 
against its numerous and highly variable strains. HCV gains entry into the liver in a 
complex process which researchers have yet to elucidate fully (Lindenbach & Rice 
2013), and ever increasing evidence suggests that the virus is also able to infect by 
direct cell-to-cell transmission (Timpe et al. 2008). Recent work has highlighted yet 
another mechanism of transmission – trans-infection of liver cells by HCV-carrying B-
lymphocytes – but little is known about the receptors and factors involved in this 
process (Stamataki et al. 2009). This project aims to investigate the mechanism of 
lymphocyte-mediated HCV trans-infection in further detail, and discover whether T-
lymphocytes can also be vehicles for HCV transmission to liver cells. 
 
1.1 HCV importance, structure and cell culture systems 
HCV infects approximately 170 million people, or ~3% of the global population 
(Mittapalli et al. 2011; Meredith et al. 2012). While HCV infection can be acute, 
around 60-80% of all cases progress onto chronic hepatitis C, which can in turn lead 
to liver steatosis, cirrhosis, hepatocellular carcinoma and liver failure within 10-30 
years of initial infection. This makes HCV a top indicator for liver transplantations 
worldwide (Meredith et al. 2012; Wilson & Stamataki 2012; Lindenbach & Rice 2013; 
Rupp & Bartenschlager 2014). Despite the slow progression of HCV-mediated liver 
damage, newly transplanted livers become re-infected with circulating HCV within 
weeks, eventually leading to graft failure and, consequently, reduction in patient 
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survival (Ciesek & Wedemeyer 2012; Wilson & Stamataki 2012). Furthermore, the 
mainstay of current HCV therapy – pegylated interferon-α with ribavirin – is not 
equally effective in all patients and carries substantial risk of side effects such as 
haemolytic anaemia and psychiatric disorders (Meredith et al. 2012; Rupp & 
Bartenschlager 2014). New direct-acting antivirals (DAA), the first ones of which were 
telaprevir and boceprevir, were approved in 2011 and directly targeted viral proteins 
necessary for the HCV life cycle. These led to higher rates of sustained virological 
response (SVR) in patients, but mainly in those infected with HCV genotype 1; in 
addition, they showed greater propensity towards side effects and development of 
viral resistance (Rupp & Bartenschlager 2014). It is not surprising, therefore, that 
much effort is going into developing new antiviral treatments and vaccines. For these 
efforts to succeed, reliable models of HCV replication in vitro and in vivo, together 
with a better understanding of the life cycle of the virus, are both needed. 
 
HCV is the sole member of the Hepacivirus genus within the Flaviviridae family of 
viruses. It is highly variable – its naturally occurring forms exhibit at least six major, 
distinct genotypes (Lindenbach et al. 2005), with genotypes 1 and 2 being distributed 
worldwide (Kato et al. 2003). HCV is an enveloped, positive-strand RNA virus, the 
genome of which is translated into a single polyprotein subsequently cleaved into 
individual structural or non-structural (NS) proteins (Lindenbach & Rice 2013). The 
structural proteins are an integral part of the virus particle and include the ‘core’ 
protein, which forms the capsid, and the two glycoproteins, E1 and E2. The NS 
proteins, on the other hand, do not integrate into the virus, instead performing 
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functions related to HCV replication inside the host cell. These are p7, NS2, NS3, 
NS4A and NS5A and –B (Lindenbach & Rice 2013). 
 
1.1.1 The evolution of the HCV cell culture system 
The study of the complex life cycle of HCV in vitro has historically been hampered by 
the inability to reproduce its many aspects in cell culture. The first functional 
complementary DNA (cDNA) clone of HCV genotype 1a was synthesised in 1997, 
and its RNA transcripts exhibited viral replication in the liver of a chimpanzee after 
direct intrahepatic injection (Yanagi et al. 1997; Kolykhalov et al. 1997). This was 
followed by generation of ‘subgenomic replicons’, or units of HCV RNA capable of 
autonomous replication. While these allowed for examination of HCV replication in 
cell culture, productive infection was not established (e.g. reviewed in Lohmann 
2009). Infectious (pseudo)-virus was first produced by displaying HCV glycoproteins 
E1 and E2 onto a retro- or lentiviral core, generating the so-called HCV pseudo-
particles (HCVpp). These were capable of entering primary hepatocytes and allowed 
for examination of putative receptors for HCV cell entry, but were not able to 
establish a spreading infection (Bartosch et al. 2003). It was not until 2005 that a full-
length HCV genome, capable of both replication and transmission of infection in cell 
culture (HCVcc), was generated (Lindenbach et al. 2005; Wakita et al. 2005). 
Lindenbach et al. also demonstrated that the newly produced HCVcc infectious 
clone, which they named J6/JFH, established productive infections in chimpanzees 
and in immunodeficient mice with human liver grafts (Lindenbach et al. 2006). 
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Most studies of HCVcc are performed on the Huh-7 hepatoma cell line which, while 
supportive of HCV replication (Blight et al. 2002), lacks some of the key features of 
primary hepatocytes, such as the ability to polarise or to form tight junctions (Mee et 
al. 2008). As such, it is unclear how representative the in vitro results are of the in 
vivo infection. The ideal study system is the liver itself, although its complexity and 
the activation of non-hepatocytes (e.g. endothelial cells, Kupffer cells) during 
inflammation introduces problems into the design of representative in vitro models 
(Meredith et al. 2012). There have, however, been advances in this field, such as co-
cultures of primary human hepatocytes and supportive stroma which were able to 
support HCV replication (Ploss et al. 2010). Suitable small animal models are also in 
development. For example, a recent study found that genetically humanised mice 
with blunted antiviral immunity were able to sustain HCV viraemia for several weeks, 
and even produce new infectious particles inhibited by DAA treatment (Dorner et al. 
2013). 
 
Regardless of the difficulties surrounding the study of the full HCV life cycle, the 
conserved nature of the first step in the cycle – host cell entry – has generated great 
interest due to its potential as a therapeutic target (Meredith et al. 2012). Studying it 
further will provide us with valuable insight into the complex mechanism employed by 
HCV to establish a productive infection. 
 
1.2 Mechanism of HCV cell entry 
While circulating in the blood, HCV comes into contact with the basolateral surface of 
hepatocytes, where its attachment and entry is initiated (Lindenbach & Rice 2013). 
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The attachment happens via interaction of the virus with low-density-lipoprotein 
receptor (LDLR) and glycosaminoglycans (GAG) on the hepatocyte cell surface, as 
evidenced by anti-LDLR antibody and desulfation of GAG both significantly reducing 
HCV adsorption in vitro (Germi et al. 2002). In addition, five surface molecules are 
needed for HCV to gain entry: CD81, scavenger receptor class B type I (SR-BI), 
claudin-1 (CLDN1), occludin (OCLN) and Niemann-Pick C1-like-1 (NPC1L1) 
(Lindenbach & Rice 2013) (Figure 1). Following successful attachment, the virus is 
internalised through the process of clathrin-mediated endocytosis. This was shown 
by inhibition of HCVcc entry into Huh-7 by either small interfering RNA (siRNA)-
mediated clathrin heavy chain depletion, or chlorpromazine-mediated inhibition of 
clathrin-coated pit formation (Blanchard et al. 2006). HCV also requires acidification 
of its endosomal compartment in order to fuse with the endosomal membrane and 
expel its genetic material into the cytosol (Tscherne et al. 2006). For example, pre-
treating Huh-7 or Huh-7.5 cells (Huh-7 cells cured with interferon as described by 
Blight et al. 2002) with bafilomycin A1, a vacuolar ATPase inhibitor known to impact 
endosome acidification, inhibited HCVcc entry into the host cell (Blanchard et al. 
2006; Tscherne et al. 2006). 
 
1.2.1 The roles of CD81 and SR-BI in HCV entry  
The first HCV receptor to be discovered was CD81, a tetraspanin (surface protein 
containing four membrane-spanning domains) ubiquitously expressed in the body, 
including on hepatocytes and B-lymphocytes (Pileri et al. 1998). It was found to bind 
to the HCV glycoprotein E2; furthermore, HCV-neutralising antibodies in vivo also 
inhibited virus attachment to CD81 in vitro (Pileri et al. 1998). While it is located on 
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the surface of many different cell types and thus makes an inherently poor drug 
target, CD81 may help define HCV species preference, or tropism, for human 
hepatocytes. For example, mice expressing human CD81 and OCLN in the liver 
became infected with HCV (Dorner et al. 2013). On the other hand, it has been 
shown that, while necessary, CD81 alone is not sufficient for HCV cell entry (Bertaux 
& Dragic 2006). Through a series of genetic mutations and imaging techniques, 
researchers demonstrated that CD81 associates with CLDN1 on the basolateral 
surface of the polarised HepG2 cell line in order to mediate HCV entry (Harris et al. 
2010). In addition to its clearly diverse roles, CD81 may prime HCV glycoproteins for 
activation by low endosomal pH, as shown by the ability of soluble CD81 to sensitise 
virus particles to acid (Sharma et al. 2011). 
 
SR-BI is highly expressed on hepatocytes, where it has a significant role in 
cholesterol uptake from its transport lipoproteins (Acton et al. 1996). It was identified 
as an important co-receptor for HCV entry when recombinant HCV E2 was shown to 
bind to it on HepG2 cells which do not express CD81 (Scarselli et al. 2002). 
Moreover, this interaction was highly selective, as neither the closely related human 
scavenger receptor CD36 nor mouse SR-BI were found to bind to E2 (Scarselli et al. 
2002). This, coupled with its high expression levels in the liver, may help define HCV 
hepatotropism (Lindenbach & Rice 2013). SR-BI is also responsible for initial HCV 
attachment via binding to viral apolipoproteins (e.g. apolipoprotein E, apoE), and 
initiates lipid transfer required for productive infection to be established (Dao Thi et 
al. 2012). It is only after this that the SR-BI/E2 interaction takes place and causes a 
conformational change in E2 that allows HCV to bind to CD81 (Dao Thi et al. 2012). 
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This is another example of the surface receptors communicating in order to mediate 
viral entry. 
 
1.2.2 HCV cell-to-cell transmission 
The HCV entry model shown in Figure 1 constantly changes to accommodate the 
ever-expanding knowledge on the process. For example, recent evidence has 
emerged of the capacity of HCV for direct cell-to-cell transmission, thus enabling it to 
evade the host’s humoral immune response (Timpe et al. 2008; Carloni et al. 2012; 
Meredith et al. 2012). The first report of this phenomenon in vitro described the HCV-
infected, human B lymphoblastoid TO.FE cell line transmitting the virus to co-cultured 
human HepG2 hepatoma cells through direct cell contact (Valli et al. 2006). HepG2 
did not express LDLR or CD81 and were thus non-permissive to cell-free HCV 
infection; this model, therefore, showed that hepatoma HCV permissiveness can be 
achieved by cell-to-cell contact with infected human B-lymphocytes (Valli et al. 2006). 
CD81, SR-BI, CLDN1 and OCLN were all found to be necessary for the cell-to-cell 
route of infection in Huh-7.5 cells (Brimacombe et al. 2011). In addition, SR-BI 
inhibition by antibodies and small molecules preferentially inhibited HCV cell-to-cell 
transmission, highlighting the significance of this surface receptor in this particular 
transmission route (Brimacombe et al. 2011). 
 
The studies above clearly show the mechanisms of HCV transmission are varied and 
complex, potentially presenting problems in the design of new therapeutic agents. 
Moreover, the ability of the virus to infect hepatocytes by transmission from B- 
lymphocytes, as initially demonstrated by Valli et al. in 2006, has recently received 
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more attention as another potentially inhibitable route this virus takes in the body. 
This infection of a cell by contact with another, infected cell rather than the infectious 
agent (i.e. virus) itself has been termed trans-infection. 
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Figure 1 – The integrated model of HCV cell entry. 
HCV engages in a series of temporally and spatially ordered interactions with several entry 
factors in order to enter hepatocytes. Lipoprotein-associated viral particles interact with SR-
BI, LDLR and GAG present on heparan sulphate proteoglycans (HSPG) to mediate initial 
attachment. SR-BI then engages in lipid transfer to possibly dissociate HCV from its 
lipoproteins, which exposes the CD81-binding domain on the HCV E2 glycoprotein. This 
activates signal transduction through epidermal growth factor receptor (EGFR), HRAS 
GTPase and RHO GTPases, which remodel actin filaments to allow CD81-bound virus to be 
transported laterally to tight junctions. Here HCV-CD81 and CLDN1 interact to induce 
clathrin-mediated endocytosis. E2-CD81 interactions within the endosome may prime the 
glycoprotein response to low endosomal pH, inducing HCV fusion with the endosomal 
membrane and the release of its RNA into the cytosol, ready for translation to viral protein. 
The roles of OCLN and NPC1L1 in the entry process are not fully understood yet. 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Microbiology 
(Lindenbach & Rice 2013), copyright © Macmillan Publishers Limited (2013)  
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1.3 Lymphocyte-mediated HCV trans-infection 
The viral infection of and transmission between lymphocytes is not a new concept. 
Rappocciolo et al. demonstrated that both HIV-1 and human herpesvirus-8 (HHV-8) 
could infect activated B-lymphocytes by endocytosis mediated by dendritic cell-
specific ICAM-3 grabbing nonintegrin (DC-SIGN) expressed on B-lymphocyte 
surface. In the case of HIV-1, this process further led to trans-infection of T-
lymphocytes with the virus (Rappocciolo et al. 2006; Rappocciolo et al. 2008). Pre-
treating B-cells with anti-DC-SIGN antibody blocked both HIV-1 trans-infection of T-
cells and HHV-8 infection of B-cells (Rappocciolo et al. 2006; Rappocciolo et al. 
2008). In the case of HCV, however, it was shown that HCVcc failed to replicate in 
primary B- and T-lymphocytes, and HCVpp did not infect a B-cell line that expressed 
high levels of CD81, SR-BI and CLDN1 (Marukian et al. 2008). Despite its inability to 
establish a productive infection in lymphocytes, it was found that B-cell-associated 
HCV readily infected hepatoma cells with increased specific infectivity (ratio of 
infectious virus particles to genomic RNA) compared to cell-free infection (Stamataki 
et al. 2009). Antibody neutralisation of SR-BI and C-type lectins DC-SIGN and L-
SIGN on B-lymphocyte surface significantly reduced B-cell-mediated HCV trans-
infection, while HCV-specific neutralising antibodies failed to do the same. This was 
consistent with HCV being internalised by B-lymphocytes in this process (Stamataki 
et al. 2009). The internalisation was confirmed in a further study when anti-CD20 
antibody rituximab, which causes B-cell lysis, led to an increase in infectious HCV 
released from these cells in vitro (Stamataki et al. 2011).  
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Recent work carried out by our group suggests that T-lymphocytes may also facilitate 
in vitro trans-infection of permissive Huh-7 and polarised HepG2-CD81 hepatoma 
cell lines (Stamataki et al. 2013, manuscript in preparation). There is, however, a 
paucity of information regarding the mechanism of trans-infection using lymphocytes 
as vectors. Speculation is further complicated by our lack of knowledge of the 
molecular processes that govern lymphocyte-hepatocyte interactions. Unanswered 
questions that stem from recent work include: i) Is lymphocyte-hepatocyte contact 
required for virus transmission? ii) Is trans-infection an active process and iii) is it 
receptor-mediated? iv) Can we inhibit trans-infection by virus-specific neutralising 
antibodies? Elucidation of why HCV B- and T-lymphocyte-mediated trans-infection 
offers an advantage for HCV infection of hepatomas compared to cell-free virus is a 
worthwhile avenue of further research. 
 
1.4 Hypothesis and aims 
Building on the work described above, we aimed to characterise the mechanism of 
lymphocyte trans-infection of hepatomas by HCVcc. We hypothesised that trans-
infection was an active process, which would be sensitive to therapeutic 
interventions. Our specific objectives were the following: 
- To compare live and dead B- and T-lymphocyte cell lines as vectors for HCVcc 
transmission to Huh-7; 
- To investigate if viral entry receptors CD81 and SR-BI on hepatomas play a role in 
trans-infection; 
- To examine the effect of HCV-specific neutralising antibodies on HCV trans-
infection of Huh-7 by B- and T- cell lines; 
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- To establish the effect of chemical and cytokine treatment on HCV trans-infection of 
Huh-7 by live or dead B- and T-lymphocyte cell lines.  
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2. MATERIALS AND METHODS 
 
2.1 Culture of hepatoma and lymphocyte cell lines 
Huh-7 hepatoma cells were cultured in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 10% foetal bovine serum (FBS), 1% penicillin with streptomycin, 
1% non-essential amino acids and 1% L-Glutamine (all Gibco, Life Technologies, 
Paisley, UK). The cells were incubated at 37°C in 5% CO2 when not in use and 
passaged two to three times a week to maintain viability and optimal growth 
conditions. 
 
Four B-lymphocyte (L3055, Raji, DG75 and KEM) and one T-lymphocyte cell line 
(Jurkat) were used. These were all cultured in Roswell Park Memorial Institute 
(RPMI) medium (Gibco) supplemented in the same way as DMEM above. They were 
kept in the same conditions and passaged with approximately the same frequency as 
Huh-7. 
 
2.2 HCVcc trans-infection and lymphocyte entry assays 
Before each experiment, Huh-7 cells were incubated with 0.25% trypsin-EDTA 
solution (Gibco) for four minutes to detach them from the flask. 10% FBS/DMEM was 
subsequently added to neutralise trypsin and prevent permanent cell damage. Cells 
were counted using a haemocytometer, with the addition of trypan blue (Sigma-
Aldrich, Poole, UK) to visualise dead cells. The amount of Huh-7 needed for each 
experiment was then removed from suspension and diluted to the appropriate 
volume with 10% FBS/DMEM before being seeded in 24- or 96-well plates as 
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required. The seeding density was chosen so as to give the cells enough space to 
grow and multiply for 48-72h. Previous lab experience showed that the adequate 
quantities for this were 3x104 and 0.75x104 Huh-7/well for a 24-well and 96-well plate 
respectively. 
 
B- and T-lymphocytes were counted in the same way as Huh-7 (trypsin-EDTA was 
not used as these cells do not adhere to plastic). The required quantities were either 
left viable or heat-killed by being exposed to a temperature of 56°C on a heat block 
for 30 minutes. Live or dead lymphocytes were subsequently incubated with HCVcc 
and added to Huh-7 (see section 2.2.1), or alternatively added directly to hepatoma 
cells (see section 2.2.2). The number of lymphocytes added per well was 0.5-1x106 
or 0.25x106, depending on whether Huh-7 were seeded in 24- or 96-well plates, 
respectively. 
 
2.2.1 Trans-infection assays and fluorescent imaging 
After seeding in 96-well plates, Huh-7 were incubated at 37°C for 24h to allow the 
cells to adhere to the plastic. After 24h various treatments with inhibitors, cytokines or 
antibodies (see section 2.3) were added to the cells for 1h before being washed off 
and replaced with 10% FBS/DMEM. At the same time, both live and dead B- and T-
lymphocytes were incubated with the SA13/JFH strain of HCVcc at 37°C for 2h in the 
category 3 containment level laboratory to allow the lymphocytes to take up the virus. 
Infected cell suspensions were then washed five times using 10% FBS/RPMI to 
remove any viral particles that did not bind. These HCVcc-carrying lymphocytes, or 
the virus alone for comparison, were subsequently added to the pre-treated Huh-7. 
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The whole plate was incubated for 48h to allow hepatoma infection, or for 72h to 
allow infection and virus spread to surrounding hepatomas. At the end of the 
incubation, the cells were fixed by adding ice-cold methanol for 5 minutes before 
replacing it with phosphate-buffered saline (PBS; Gibco). In order to visualise 
infected Huh-7, the following labelling protocol was performed: 
1) Primary mouse immunoglobulin G3 (IgG3) antibody binding to HCV NS5A 
protein (gift from Jane McKeating, University of Birmingham) was added for 30 
minutes before being washed off; 
2) Secondary anti-mouse IgG3 antibody conjugated to Alexa Fluor 488 green 
dye (Invitrogen, Life Technologies, Paisley, UK) was added for 30 minutes 
before being washed off and replaced with PBS. 
The plate was then ready for examination using a Nikon fluorescent microscope. The 
number of green-fluorescing clusters of infected cells, called focus-forming units 
(FFU) (Figure 2), was determined for each well, and means were calculated from two 
or three replicates for each condition. 
 
2.2.2 Lymphocyte entry assays and confocal imaging 
A series of assays on lymphocyte entry into hepatomas was run in parallel with trans-
infection assays in order to establish a possible correlation between the mechanisms 
of entry and trans-infection. For this set of experiments we only used Jurkat T-
lymphocytes. To visualise their entry into hepatomas, Huh-7 cells and Jurkat T-cells 
were labelled using CellTracker™ Green CMFDA and CellTracker™ Red CMTPX 
(both Invitrogen) respectively. Briefly, the cells would be placed in 5µM CellTracker™ 
solution in serum-free media (SFM) for 45 minutes, after which SFM would be 
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replaced with 10% FBS/DMEM to quench the labelling reaction. Once all the cells 
were appropriately labelled, Huh-7 were seeded onto glass coverslips in a 24-well 
plate and placed in SFM for 1h, while Jurkat T-cells were either left alive or heat-
killed as described. Following serum starvation of Huh-7, reagents that either 
boosted or inhibited lymphocyte uptake by hepatomas (see section 2.3) were added 
to the wells for 1-2h before being washed off and replaced with 10% FBS/DMEM.  
Live or dead T-lymphocytes were then incubated with Huh-7 for 2-4h to allow their 
entry into the hepatomas. The cells were subsequently fixed with methanol or 1% 
paraformaldehyde (PFA; Sigma-Aldrich, Poole, UK) as described in section 2.2.1.  
 
We left some wells lymphocyte-free to help us visualise the actin cytoskeleton and 
the nuclei of the hepatomas and thus gain a better understanding of the action of the 
reagents on these cell components. To do this, we added 0.3% Triton™-X 100 
(Sigma-Aldrich) in PBS to PFA-fixed Huh-7 for 5 minutes to render them permeable 
to dye. The detergent was then removed and a PBS solution of red Alexa Fluor 
Phalloidin 568 (Life Technologies, Paisley, UK) applied for approximately 1h to allow 
phalloidin to bind to F-actin inside the cell. This was also removed and followed by 
application of the blue nuclear stain, DAPI (Life Technologies) in PBS for 5 minutes. 
Once the staining was complete, the glass coverslips were mounted onto slides 
using Fluorescence Mounting Medium (Dako, Ely, UK) and examined using a 
confocal microscope (LSM780, Carl Zeiss). The images were obtained and analysed 
using ZEN software (Figures 3 and 4). 
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Figure 2 – Defining a focus-forming unit of HCVcc-infected Huh-7 cells. 
Huh-7 cells were incubated with live or dead HCVcc-carrying B- or T-lymphocytes for 72h. 
The cells were subsequently fixed with methanol and stained using primary mouse anti-
NS5A IgG3 and secondary anti-mouse IgG3 conjugated to Alexa Fluor 488 green dye. The 
cells were then studied using a Nikon fluorescent microscope. Cell nuclei can be seen in blue 
(DAPI). Clusters of infected cells called focus-forming units (FFU) were apparent when Huh-
7 successfully transmitted the infection to neighbouring cells. Single infected cells were also 
observed when transmission was poor (not shown). 
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Figure 3 – Imaging F-actin in Huh-7 cells. 
Huh-7 cells were stained using CellTracker™ Green CMFDA, and their actin cytoskeleton 
and nuclei visualised with red Alexa Fluor Phalloidin 568 and blue DAPI dye, respectively. 
From top left: Huh-7 nuclei (blue), actin cytoskeleton (red), cytoplasm (green) and merged 
image of a Huh-7 monolayer. 
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Figure 4 – Imaging phagocytosis of dead lymphocytes in Huh-7 cells. 
Huh-7 and Jurkat T-cells were stained using CellTracker™ Green CMFDA and CellTracker™ 
Red CMTPX respectively before being incubated together to allow the lymphocytes to enter 
the hepatoma cells. The nuclei of all cells were visualised with blue DAPI dye. From top left: 
cell nuclei (blue), dead Jurkat T-lymphocytes (red), Huh-7 cytoplasm (green) with obvious 
vacuoles where T-lymphocytes have internalised, and merged image showing phagocytosis 
of dead Jurkat T-cells by the hepatoma cells. 
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2.3 Reagents 
As part of trans-infection assays, Huh-7 were treated with chemicals and cytokines 
that could impact on their ability to take up extracellular material – in this case, 
lymphocytes and viral particles. Additionally, a SR-BI inhibitor and antibodies against 
HCV itself or CD81 were also tested. The specific reagents, their exact functions and 
concentrations are listed in Table 1. 
 
In addition to some of the reagents above, actin polymerisation inhibitors were added 
to Huh-7 in lymphocyte entry assays, with the aim of assessing the impact this had 
on the ability of hepatomas to engulf lymphocytes. These inhibitors and their working 
concentrations are listed in Table 2. 
 
2.4 Statistical analysis 
All data were analysed using GraphPad Prism 5 and expressed as mean ± standard 
error of the mean (SEM). Analysis of variance (ANOVA) was used to assess variation 
between multiple conditions and Bonferroni post-tests to compare individual 
treatments, as appropriate. Statistical significance was assumed if P < 0.05. Where 
ANOVA did not show statistical significance for any of the parameters, no mention of 
it was made in the figure legends. 
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Table 1 – Chemical treatments, cytokines and antibodies added to Huh-7 cells during 
trans-infection assays 
Reagent Function Manufacturer 
Working 
concentration 
Chemicals/cytokines 
Amiloride 
Macropinocytosis 
inhibitor 
Sigma-Aldrich 0.5mM 
Bafilomycin A1 
Endosome 
acidification 
inhibitor 
Sigma-Aldrich 100nM 
ITX5061 SR-BI inhibitor 
iTherX, San 
Diego, 
California, USA 
10-20µM 
Secretory leukocyte 
protease inhibitor 
(SLPI) 
Phagocytosis 
potentiator 
PeproTech, 
Rocky Hill, New 
Jersey, USA 
1µM 
Tumour necrosis factor α 
(TNFα) 
Phagocytosis 
potentiator 
" 10ng/mL 
Antibodies 
Anti-CD81  
clones 2-s131 and 2-s337 
Anti-CD81 IgG 
McKeating, 
University of 
Birmingam, UK 
5µg/mL 
BT003 
HCV-specific 
polyclonal human 
IgG 
Biotest, 
Solihull, UK 
100µg/mL 
BT001 
Non-specific 
polyclonal human 
IgG (isotype control 
for BT003) 
" 100µg/mL 
Nanobody 
Broadly 
neutralising HCV-
specific heavy-
chain antibody 
The University 
of Nottingham, 
UK 
100µg/mL 
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Table 2 – Actin polymerisation inhibitors added to Huh-7 cells during lymphocyte 
entry assays 
Inhibitor Manufacturer Working concentration 
Cytochalasin-D 
Cambridge Bioscience, 
Cambridge, UK 
10µM 
Latrunculin-A " 1µM 
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3. RESULTS 
 
3.1 HCVcc-carrying dead lymphocytes can lead to efficient trans-
infection of hepatoma cells 
Previous work from our laboratory has shown that B-cells (Stamataki et al. 2009) and 
T-cells (unpublished) can transmit HCVcc in trans to hepatoma cells in vitro. We first 
set out to investigate if the lymphocytes needed to be alive for this trans-infection to 
occur. We added live or dead HCVcc-carrying B-lymphocytes to Huh-7 cells seeded 
in a 24-well plate, allowed infection to occur for 72h and then fixed and stained cells 
for viral protein to measure infection. Four different B-lymphocyte cell lines – Raji, 
L3055, DG75 and KEM – were used for comparison, and infection was quantified as 
FFU/well (Figure 5A). Trans-infection by live cells indicated that Raji cells and, to a 
lesser extent, DG75 cells, but not L3055 or KEM cells were capable of trans-
infection. Interestingly, heat-killed lymphocytes apart from KEM cells all transmitted 
HCVcc infection at similar levels – about two-fold less than transmission seen by live 
Raji cells. Live or dead KEM cells did not transmit infection, indicating that this cell 
line may not capture HCV. This experiment shows that heat-killed lymphocytes can 
transmit HCVcc infection to hepatomas in vitro. 
 
To further characterise the infection established by each type of B-lymphocyte, the 
size of the foci was also measured. Since FFU consisting of two cells were most 
likely derived from one infected cell which subsequently underwent division, the foci 
which contained more than two fluorescing cells at 72h post-infection were 
considered to show actual transmission of the virus. These large, or ‘transmitting’ 
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foci, were counted for each type of B-lymphocyte apart from KEM (see above), and 
their number compared to the total number of foci in order to get an estimate of 
percentage of transmission (Figure 5B). This was close to 40% for all but the live 
L3055. Importantly, the difference in transmission between live and dead B-cells was 
not significant for any of the three cell lines, showing that the presence of dead 
lymphocytes in co-culture with hepatomas can also lead to efficient HCVcc 
transmission. 
 
Raji and L3055 cells, showing the highest and lowest trans-infection potential 
respectively, were used for further studies. The same set of experiments was 
repeated with these two cell lines and the Jurkat line of T-lymphocytes, in order to 
compare the trans-infection potential of B- and T-cells. Huh-7 were seeded in a 96-
well plate in this and all subsequent trans-infection assays, resulting in lower 
numbers of lymphocytes used per well – this is reflected in the results. 
 
Consistent with previous findings, the presence of live Raji cells resulted in 
significantly greater numbers of infected FFU compared to dead Raji (Figure 6). 
L3055, on the other hand, transmitted the infection to Huh-7 to approximately the 
same extent whether live or dead. Jurkat T-cells exhibited a very similar trans-
infection pattern to that of the Raji. Even though the number of infected foci was not 
high for any of the dead cell lines examined, it was still significant enough to establish 
a successful infection. This indicated, once again, that the presence of virus-carrying 
lymphocytes can result in successful HCVcc infection of Huh-7 even when the 
vehicles for that infection have been killed. 
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Figure 5 – Dead lymphocytes can trans-infect Huh-7 cells with HCVcc.  
Four different B-lymphocyte cell lines (Raji, L3055, DG75 and KEM) carrying HCVcc were 
added to Huh-7 (106 lymphocytes/well) to assess the potential of lymphocytes to transmit 
HCV infection to hepatomas. Infection was allowed to occur for 72h and was measured by 
NS5A staining. (A) Average number of infected focus-forming units (FFU)/well after 
treatment with either live or dead B-lymphocytes of each cell line. Two-way ANOVA showed 
a significant effect of both B-lymphocyte type (P<0.0001) and viability (P<0.05) on trans-
infection. * = P<0.05 and ** = P<0.01 by Bonferroni post-tests. (B) Average percentage (from 
total FFU) of FFU showing transmission (>2 infected cells/focus) after treatment with either 
live or dead B-lymphocytes of each cell line. Two-way ANOVA showed a significant effect of 
B-lymphocyte type (P<0.01), but not viability, on trans-infection. Data are mean ± SEM from 
two replicates, n=1. 
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Figure 6 – Live and dead T-lymphocytes as well as B-lymphocytes can trans-infect 
hepatomas with HCVcc. 
Jurkat T-lymphocytes and Raji and L3055 B-lymphocytes carrying HCVcc were added to 
Huh-7 (0.25x106 lymphocytes/well) to assess the potential of lymphocytes to transmit HCV 
infection to hepatomas. Infection was allowed to occur for 48h and was measured by NS5A 
staining. The average number of FFU/well was plotted for Huh-7 treated with either live or 
dead lymphocytes of each cell line. Two-way ANOVA showed a significant effect of 
lymphocyte viability (P<0.01), but not type, on trans-infection. ** = P<0.01 by Bonferroni post-
tests. Data are mean ± SEM, n=5. 
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3.2 HCVcc transmission to hepatomas by lymphocytes is receptor-
dependent 
To elucidate the importance of HCV attachment receptors CD81 and SR-BI in 
lymphocyte-mediated HCVcc infection, we treated Huh-7 with two different clones of 
anti-CD81 antibody (2-s131 or 2-s337), or the SR-BI inhibitor ITX5061, before the 
addition of virus-carrying lymphocytes or virus alone (Figure 7). Both clones of anti-
CD81 were more potent inhibitors of HCVcc infection than ITX5061, although the 
differences in the extent of neutralisation achieved with these two treatments were 
not statistically significant. Anti-CD81 antibodies were less successful in inhibiting the 
infection when live L3055 were present, with 2-s337 not achieving any neutralisation 
in this lymphocyte subset. ITX5061 appeared to work better when dead lymphocytes 
were the carriers of infection. Overall, however, the levels of neutralisation for all 
three inhibitors were similar in the presence of live or dead lymphocytes. The 
capacity of the inhibitors to neutralise cell-free infection (i.e. without lymphocytes) 
was also examined for comparison (Figure 7C). All three were very effective, with 
ITX5061 achieving almost 80% and the two anti-CD81 antibodies virtually 100% 
neutralisation.  
 
CD81 inhibition was therefore highly efficient for both cell-free virus and trans-
infection, however ITX5061 was not as efficient in preventing trans-infection 
compared to cell-free virus infection. Taken together, this work shows that trans-
infection by live and dead lymphocytes uses receptor-mediated mechanisms for 
HCVcc infection of hepatomas.  
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Figure 7 – Trans-infection by live and dead lymphocytes is receptor-mediated. 
Huh-7 cells were left untreated or pre-treated with one of two clones of anti-CD81 antibody, 
or the SR-BI inhibitor ITX5061, before HCVcc-carrying lymphocytes (live or dead) or virus 
alone were added to them. Infection was allowed to occur for 48h and was measured by 
NS5A staining. The average numbers of FFU/well were compared between each treatment 
and controls (isotype-matched antibody for anti-CD81 or DMSO vehicle for ITX5061) and 
plotted as % FFU that were neutralised relative to control-treated Huh-7 for (A) live 
lymphocytes, (B) dead lymphocytes and (C) no lymphocytes (HCVcc alone). Data are mean 
± SEM. n=2 for anti-CD81 2-s131 and ITX5061 in live and dead lymphocytes. n=1 for anti-
CD81 2-s337 and for all treatments with no lymphocytes present.  
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3.3 HCVcc trans-infection is sensitive to neutralisation by virus-specific 
antibodies 
To test if lymphocyte-transmitted virus was susceptible to neutralising antibodies, we 
used BT003, a HCV-specific polyclonal human IgG, and a HCV-specific nanobody 
(Tarr et al. 2013) to treat Huh-7 before adding the virus-infected lymphocytes or virus 
alone (Figure 8). Both antibodies, and especially the nanobody, showed effective 
inhibition of HCVcc infection across the board. The smallest effect was once again 
seen in live L3055 cells. BT003 seemed to work somewhat better in the presence of 
dead lymphocytes compared to live cells. For comparison, when the two antibodies 
were tested against hepatoma infection caused by HCVcc alone, both displayed 
virtually 100% inhibition (Figure 8C). The data obtained therefore showed that, like 
cell-free infection, HCV trans-infection by live and dead lymphocytes can also be 
successfully inhibited by HCV-specific antibody neutralisation. 
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Figure 8 – Trans-infection by live and dead lymphocytes is susceptible to antibody 
neutralisation. 
Huh-7 cells were pre-treated with HCV-specific polyclonal human IgG (BT003) or HCV-
specific nanobody before virus-carrying lymphocytes (live or dead) or virus alone were added 
to them. Infection was allowed to occur for 48h and was measured by NS5A staining. The 
average numbers of FFU/well were compared between each treatment and controls treated 
with non-specific polyclonal human IgG, and plotted as % FFU that were neutralised relative 
to control for (A) live lymphocytes, (B) dead lymphocytes and (C) no lymphocytes (HCVcc 
alone). (A), two-way ANOVA showed a significant effect of the type of neutralising antibody 
(P<0.01), but not lymphocyte type, on trans-infection. Data are mean ± SEM from three 
replicates, n=1. 
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3.4 Defining the mechanism of trans-infection by live and dead 
lymphocytes 
Hepatocytes are phagocytic cells and internalise dead lymphocytes as early as 1h 
following co-culture (effect seen in Figure 4). We wanted to establish if phagocytosis 
played a role in HCVcc entry to hepatomas, or if trans-infection by live and dead T-
cells was mechanistically comparable. In the absence of specific inhibitors for 
phagocytosis, we set out to establish the role of acidification and macropinocytosis 
mechanisms in trans-infection.  We treated Huh-7 with bafilomycin A1, an endosomal 
acidification inhibitor that prevents viral fusion with the endosome and pH-dependent 
viral entry (Baldick et al. 2010), or amiloride, a known inhibitor of membrane ruffling 
and macropinocytosis (West et al. 1989). Either treatment inhibited both lymphocyte-
mediated and cell-free trans-infection very efficiently, with no significant differences 
between any of the conditions (Figure 9). As treatments inhibited cell-free virus entry, 
we could not deduce the role of internalisation of dead cells in trans-infection. 
 
Recent unpublished data from our lab suggested that tumour necrosis factor alpha 
(TNFα) and secretory leukocyte protease inhibitor (SLPI), when given together, 
potentiated phagocytosis of lymphocytes by Huh-7 cells (Weight et al., manuscript in 
preparation). We therefore treated the hepatomas with this combination treatment to 
examine whether it had an impact on lymphocyte-mediated HCVcc trans-infection. In 
parallel, we used confocal microscopy to confirm phagocytosis of dead Jurkat T-
lymphocytes by Huh-7 cells after combined treatment with TNFα and SLPI.  
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In our trans-infection assay, we observed no significant potentiation of infection in 
any of the lymphocyte cell lines, whether live or dead (Figure 10). In fact, treatment 
with TNFα and SLPI in the presence of live Jurkat or Raji resulted in a slight 
decrease in the number of infected foci compared to untreated Huh-7, although this 
was not significant. Similarly, the treatment had no effect on cell-free infection. In the 
parallel lymphocyte entry assay, we were not able to see an increase or decrease in 
phagocytosis of dead T-cells by TNFα/SLPI-treated compared to untreated 
hepatomas (data not shown). We were therefore unable to draw meaningful 
conclusions from the result of this first experiment. More work is needed with 
matching phagocytosis and trans-infection experiments run in parallel in order to 
establish any effects of TNFα and SLPI on trans-infection. 
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Figure 9 – Effect of inhibition of pH-dependent entry or macropinocytosis on HCVcc 
trans-infection in Huh-7 in the presence or absence of live or dead lymphocytes. 
Huh-7 cells were left untreated or pre-treated with bafilomycin A1 or amiloride before HCVcc-
carrying lymphocytes (live or dead) or virus alone were added to them. Infection was allowed 
to occur for 48h and was measured by NS5A staining. The average numbers of FFU/well 
were compared between each treatment and untreated controls and plotted as % FFU that 
were neutralised relative to untreated Huh-7 for (A) live lymphocytes, (B) dead lymphocytes 
and (C) no lymphocytes (HCVcc alone). (A), two-way ANOVA showed a significant effect of 
the type of treatment (P<0.01), but not lymphocyte type, on trans-infection. Data are mean ± 
SEM from three replicates, n=1. 
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Figure 10 – Effect of combined treatment of TNFα and SLPI on HCVcc trans-infection 
in Huh-7 in the presence or absence of live or dead lymphocytes. 
Huh-7 cells were left untreated or pre-treated with a combination of tumour necrosis factor 
alpha (TNFα) and secretory leukocyte protease inhibitor (SLPI) before HCVcc-carrying 
lymphocytes (live or dead) or virus alone were added to them. Infection was allowed to occur 
for 48h and was measured by NS5A staining. The average numbers of FFU/well were 
compared between the treatment and untreated controls in the presence of (A) live 
lymphocytes, (B) dead lymphocytes and (C) no lymphocytes (HCVcc alone). (A), two-way 
ANOVA showed a significant effect of both treatment (P<0.05) and lymphocyte type (P<0.01) 
on trans-infection. Data are mean ± SEM. n=2 for Jurkat T-lymphocytes and cell-free 
infection (HCVcc alone). n=1 for Raji and L3055 B-lymphocytes. 
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3.5 The actin cytoskeleton of Huh-7 is important for HCVcc trans-
infection by live and dead lymphocytes 
We wished to examine the role of the actin cytoskeleton in hepatomas on HCVcc 
trans-infection, and whether the extent of infection correlated with the ability of Huh-7 
to take up dead lymphocytes by phagocytosis. We therefore treated the hepatoma 
cells with actin polymerisation inhibitors latrunculin-A (lat-A) or cytochalasin-D (cyt-
D), both of which would prevent phagocytosis, before adding live or dead Jurkat T-
lymphocytes or virus alone. As before, we used confocal microscopy in parallel to 
look at lymphocyte entry into cells after the above treatments were applied. 
 
Both inhibitors showed very similar levels of neutralisation of infection (close to 40%) 
under all the examined conditions (Figure 11), although more variability in 
neutralisation was seen in the presence of dead T-cells. Studying the confocal 
images revealed a significant impact on the actin cytoskeleton of Huh-7 by both lat-A 
and cyt-D compared to untreated controls, although lat-A appeared to have a more 
potent effect (Figure 12). When Jurkat T-cells were present they were taken up by 
Huh-7 in the absence of inhibitors, but clustered on the outside of the hepatoma cells 
when the actin microfilaments were disrupted. This held true for both live (Figure 13) 
and dead lymphocytes (Figure 14), although uptake of live lymphocytes by Huh-7 
was rarely seen in untreated controls in the first place. We concluded that the actin 
cytoskeleton is important for HCVcc infection of hepatomas, either by cell-free virus 
or by trans-infection via lymphocyte vectors. However, we were not able to find a role 
for phagocytosis of dead lymphocytes in this process. 
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Figure 11 – Effect of inhibition of actin polymerisation on HCVcc trans-infection in 
Huh-7 in the presence or absence of live or dead lymphocytes. 
Huh-7 cells were left untreated or pre-treated with actin polymerisation inhibitors latrunculin-A 
(lat-A) or cytochalasin-D (cyt-D) before live or dead HCVcc-carrying Jurkat T-lymphocytes, or 
virus alone, were added to them. Infection was allowed to occur for 48h and was measured 
by NS5A staining. The average numbers of FFU/well were compared between each 
treatment and untreated control and plotted as % FFU that were neutralised relative to 
untreated Huh-7. Data are mean ± SEM from three replicates, n=1. 
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Figure 12 – Representative confocal images of actin polymerisation disruption in Huh-
7. 
Huh-7 were stained using CellTracker™ Green CMFDA before being treated with lat-A or 
cyt-D. The actin cytoskeleton and the nuclei of Huh-7 cells were visualised with red Alexa 
Fluor Phalloidin 568 and blue DAPI dye, respectively. Each row, from left to right: Huh-7 
cytoplasm (green), actin cytoskeleton (red), nuclei (blue), and merged image with scale bar. 
Actin microfilament disruption is visible with both lat-A and cyt-D. 
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Figure 13 – Chemical disruption of the actin cytoskeleton prevents internalisation of 
live T cells by hepatomas. 
Huh-7 and Jurkat T-lymphocytes were stained using CellTracker™ Green CMFDA and 
CellTracker™ Red CMTPX respectively before being incubated together to allow the 
lymphocytes to enter the hepatoma cells. The nuclei of all cells were visualised with blue 
DAPI dye. Each row, from left to right: Huh-7 cytoplasm (green), live Jurkat T-lymphocytes 
(red, with some background staining of Huh-7), nuclei (blue), and merged image with scale 
bar. 
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Figure 14 – Chemical disruption of the actin cytoskeleton prevents phagocytosis of 
heat-killed T cells by hepatomas. 
Huh-7 and Jurkat T-lymphocytes were stained using CellTracker™ Green CMFDA and 
CellTracker™ Red CMTPX respectively before being incubated together to allow 
phagocytosis. The nuclei of all cells were visualised with blue DAPI dye. Each row, from left 
to right: Huh-7 cytoplasm (green), dead Jurkat T-lymphocytes (red), nuclei (blue), and 
merged image with scale bar. 
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4. DISCUSSION 
In this project we used the fully replicating and infective HCV in cell culture (HCVcc) 
(Lindenbach et al. 2005; Jensen et al. 2008) to study the recently highlighted 
phenomenon of lymphocyte-mediated trans-infection of hepatomas in more detail. To 
model hepatocytes we utilised the ‘gold-standard’ permissive Huh-7 cells, a 
monolayer-forming, non-polarised tumour cell line which provides an excellent 
platform for studying HCV infection. We were able to demonstrate for the first time 
that HCV trans-infection of Huh-7 cells by both live and dead lymphocytes is 
sensitive to entry receptor inhibition and antibody neutralisation. We also examined 
alternative treatments with possible impact on this process and concluded that the 
actin cytoskeleton plays a significant role in trans-infection as well as cell-free 
infection. Further studies are needed to fully characterise HCV transmission to and 
between hepatocytes by lymphocyte vectors, potentially leading to novel therapeutic 
approaches in the treatment of this virus. 
 
4.1 Live and dead B-lymphocytes exhibit different HCVcc trans-infection 
potentials but similar transmission kinetics 
We examined whether incubation of Huh-7 with HCVcc-carrying live or dead B-
lymphocyte cell lines resulted in productive infection in the hepatomas. Consistent 
with previous findings (Stamataki et al. 2009), B-lymphocytes led to successful Huh-7 
trans-infection with HCVcc, but only when Raji or, to a much lesser extent, DG75 
cells were used as virus carriers. This points to heterogeneities in the ability to 
mediate HCV trans-infection between B-cell subsets. The fact that heat-killing the B-
lymphocyte cell lines nearly abolished the difference in trans-infection seen between 
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them when they were viable is interesting. It could mean that there were distinct 
lymphocyte-mediated trans-infection mechanisms depending on lymphocyte viability. 
B-cells are professional antigen-presenting cells (APCs), and live B-cells from 
different sources may have different antigen processing ability. For example, it is 
possible the KEM line was incapable of capturing virus particles, as it did not trans-
infect when alive or dead. Conversely, the L3055 B-cells, Raji B-cells and Jurkat T-
cells may capture the same amount of virus since they transmit equally well when 
dead. However, while alive, it is possible that L3055 degrade more virus through 
antigen processing or shed less virus than Raji and Jurkat, hence failing to transmit 
as well when alive. Quantitative polymerase chain reaction (qPCR) measurements of 
viral RNA captured by these cell lines while alive and when dead would shed light on 
these hypotheses. 
 
We also wanted to establish whether the kinetics of virus transmission to hepatomas 
differed between live and dead B-lymphocytes by looking at the size of focus-forming 
units after 72h. The fact that all B-cell lines apart from KEM resulted in almost equal 
FFU size, whether live or dead, could suggest that transmission by live and dead B-
lymphocytes occurred at similar times, allowing virus to spread from infected 
hepatomas and generate comparable foci at 72h. This would be in conflict with 
distinct mechanisms of trans-infection existing for live and dead lymphocytes 
suggested above. Alternatively, phagocytosis may allow hepatocyte infection at 
similar times as cell-free virus entry. HCVcc has been reported to enter Huh-7 cells 
as early as 20-60 minutes post-attachment (Farquhar et al. 2012), while unpublished 
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work from our lab indicates that Huh-7 cells can phagocytose dead lymphocytes as 
early as 30 minutes of co-culture.  
 
4.2 B- and T-lymphocytes may cause HCVcc trans-infection of 
hepatomas by virus internalisation 
Next we compared the trans-infection potential of T-lymphocytes with that of B-
lymphocytes. Jurkat T-lymphocytes caused almost identical levels of infection in Huh-
7 as Raji B-lymphocytes, suggesting that these two activated cell types may share 
the same trans-infection mechanism. Stamataki et al. have previously shown that, 
despite its inability to establish a productive infection in lymphocytes in vitro, HCVcc 
is internalised into B-cells (Stamataki et al. 2009; Stamataki et al. 2011). Another 
study (Sarhan et al. 2012) found that patient-derived HCV can also gain entry into T-
cells, and seemed to suggest that the virus is in fact capable of propagating in this 
cell compartment. Therefore, HCV may be internalised into live B- and T-lymphocytes 
both, and subsequently transmitted to Huh-7. Our observation that, upon heat-killing, 
the levels of trans-infection with Jurkat T- and Raji B-cells were very similar to those 
observed in the poorly transmitting L3055 B-cell line, suggests that this particular 
mechanism of transmission may be an active process that was lost on cell death. 
 
4.3 Lymphocyte-mediated HCVcc trans-infection is more dependent on 
CD81 than SR-BI 
We found that lymphocyte-mediated trans-infection depended on both CD81 and SR-
BI. SR-BI had previously been found to be crucial for HCV entry into hepatocytes 
(Scarselli et al. 2002; Dao Thi et al. 2012), which we confirmed by showing high 
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levels of neutralisation of cell-free HCVcc infection when SR-BI was inhibited. 
However, this neutralisation – although still present – was markedly reduced in 
lymphocyte-mediated trans-infection, especially when the lymphocytes were viable. It 
could be that careful titration of SR-BI inhibitor ITX5061 may reveal additional 
differences in its potential to inhibit cell-free and lymphocyte-mediated HCVcc entry. 
In addition, previous work showed that SR-BI inhibition preferentially reduced cell-to-
cell HCV transmission otherwise resistant to neutralising antibodies (nAbs) 
(Brimacombe et al. 2011). The fact that this inhibition was not as effective in trans-
infection suggests a mechanism other than cell-to-cell HCV transmission is taking 
place. Conversely, anti-CD81 antibody proved effective in both cell-free infection and 
lymphocyte-mediated trans-infection. The role of this receptor in HCV entry is well-
established (Pileri et al. 1998; Harris et al. 2010), but its impact on cell-to-cell 
transmission is more controversial. While some studies found it necessary for this 
process (Russell et al. 2008; Brimacombe et al. 2011), others showed that it may be 
partially or completely dispensable (Timpe et al. 2008; Witteveldt et al. 2009). This 
conflicting evidence may be due to differing viral strains, nAbs and origins of cells 
used for the different studies. Nevertheless, none of the studies above looked at 
heterologous HCV transmission from lymphocytes to hepatoma cells, where we 
found that CD81 inhibition does play a role almost independently of lymphocyte 
viability. Further work is, however, necessary to elucidate the exact involvement of 
CD81 and SR-BI in trans-infection. 
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4.4 Lymphocyte-mediated HCVcc trans-infection is susceptible to 
antibody neutralisation 
Our model showed high susceptibility to neutralising antibodies, both a HCV-specific 
polyclonal antibody derived from pooled patient IgG (BT003) and a recently 
discovered broadly neutralising heavy-chain alpaca antibody (nanobody). The 
nanobody had previously shown potent inhibition of both cell-free HCV entry and cell-
to-cell transmission by interfering with the CD81 binding site on the virus (Tarr et al. 
2013). Consistent with this, the reduction in HCV cell-free infection and trans-
infection with both CD81 inhibition and nanobody-mediated neutralisation was 
reflected in our results. The reduced effectiveness of BT003 in live lymphocyte-
mediated trans-infection could show some resistance of the virus to this nAb, 
therefore suggesting cell-to-cell HCV transmission may be taking place as previously 
described (Brimacombe et al. 2011). Once again, however, this study did not 
examine heterologous lymphocyte–Huh-7 viral transfer, which may possess a distinct 
mechanism of transmission to that exhibited by neighbouring hepatomas, and 
therefore possibly be more sensitive to nAb neutralisation. It would be useful to 
directly compare neutralisation titres (IC50 measurements) between cell-free infection 
and trans-infection for BT003 and for the alpaca nanobody. This would help 
determine which mode of transmission is least susceptible to neutralisation using 
specific antibodies, which would in turn be useful for the design of B-cell vaccines. 
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4.5 Defining the mechanism of lymphocyte-mediated HCVcc trans-
infection 
The inhibitory concentrations of amiloride and bafilomycin A1 used in this study had 
been previously determined in titration experiments by other members of the lab for 
the purpose of measuring cell-free HCVcc infection. It is therefore possible that the 
same concentrations were toxic to lymphocytes carrying the virus, resulting in cell 
death which manifested as apparent reduction in hepatoma infection. These 
compounds were, however, not toxic to hepatomas at the concentrations tested. 
Dose titration of both chemicals is needed before meaningful conclusions can be 
drawn from their trans-infection inhibition.  
 
On the other hand, there is growing evidence that pro-inflammatory cytokines such 
as TNFα and interferon-gamma (IFNγ) work either individually or together to induce 
tight junction remodelling and change CLDN1 and OCLN expression in several 
epithelial and endothelial cell types (e.g. reviewed in Walsh et al. 2000 and Capaldo 
& Nusrat 2009). However, little is known about their impact on hepatocytes. Our 
group recently observed that both TNFα/IFNγ and TNFα/SLPI combinations may 
increase phagocytosis of dead lymphocytes by Huh-7 cells (Weight et al., manuscript 
in preparation). In addition to cytokine effects on actin cytoskeleton, it was previously 
shown that cortical actin modification is a necessary step for HCV internalisation via 
its interaction with CD81 and TJ proteins CLDN1 and OCLN (Brazzoli et al. 2008; 
Farquhar et al. 2012) (Figure 1). Drawing on all of the above evidence, we examined 
whether changes in actin cytoskeleton impacted on lymphocyte uptake by Huh-7, 
and whether this played a role in lymphocyte-mediated HCVcc trans-infection. 
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Because the antiviral action of IFNγ would make it difficult to interpret our results, we 
focused on treatment with TNFα/SLPI, as well as direct inhibition of actin 
polymerisation by lat-A and cyt-D.  
 
In contrast to previous findings, we were not able to see an effect of TNFα/SLPI on 
phagocytosis of dead lymphocytes, or a significant impact on either cell-free HCV 
infection or lymphocyte-mediated trans-infection. As SLPI is a very unstable enzyme, 
this could be due to reagent degradation. More studies of phagocytosis and trans-
infection performed in parallel, and incorporating dose titrations of this combination 
treatment, would be needed before conclusions can be made on its effect. However, 
lat-A and cyt-D disrupted actin microfilaments as expected, resulting in moderate 
inhibition of trans-infection mediated by both live and dead Jurkat T-lymphocytes. 
This, along with the same level of inhibition exhibited for cell-free HCV infection, 
suggests that phagocytosis of dead lymphocytes may not play a role in HCVcc trans-
infection of hepatomas. Very little is known about hepatocyte phagocytosis of dead 
cells, however, and identifying specific pathways that perturb this process in order to 
examine whether they play a role in viral entry could provide us with further insight 
into HCV infection of liver cells. 
 
4.6 Future studies 
A lot still remains to be elucidated about HCV entry into hepatocytes via the trans-
infection route. We showed that B- and T-lymphocytes are capable of transmitting 
HCVcc infection to hepatomas, but the way in which they do this remains poorly 
defined. For example, the so-called ‘virological synapses’ have been found to have a 
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role in virus entry into lymphocytes (Dustin & Cooper 2000; Piguet & Sattentau 
2004), and the more recently discovered membrane nanotubules permitted the 
sequential spread of HIV-1 through T-cells (Sowinski et al. 2008). It would be 
interesting to examine the potential role of these in HCV-lymphocyte interactions, 
even if they do not result in productive infection within the lymphocytes themselves. 
This, in turn, could provide us with clues as to what may happen at the point of HCV 
transmission from lymphocytes to hepatocytes. 
 
As mentioned previously, dose titration experiments with the reagents used in this 
study, in particular the SR-BI inhibitor ITX5061, bafilomycin A1, amiloride and 
TNFα/SLPI would increase our understanding of how these chemicals impact on the 
trans-infection potential of lymphocytes compared to cell-free HCV infection. In 
addition, we looked at the role of CD81 and SR-BI but not at that of CLDN1 and 
OCLN in the trans-infection process. Inhibiting these and observing the effect on 
lymphocyte-mediated HCV infection would be the logical next step. We also identified 
that the actin cytoskeleton plays a role in trans-infection, but have not yet elucidated 
the extent of this involvement. RHO GTPases are known to mediate actin 
remodelling during HCV entry (Brazzoli et al. 2008; Farquhar et al. 2012; Lindenbach 
& Rice 2013), so inhibiting the action of these could be an interesting avenue of 
further trans-infection research. Finally, polarisation of hepatocytes is crucial for 
normal functioning of the liver in vivo, and limits HCV entry in vitro; this suggests that 
polarity perturbation in the liver may increase its propensity towards HCV infection 
(Meredith et al. 2012). Comparing the results from this study to a similar one done on 
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polarised HepG2 cells in the future could give us important insights into how altering 
hepatocyte polarisation may influence HCV trans-infection. 
 
4.7 Conclusion 
We confirmed that both B- and T-lymphocytes can mediate HCVcc trans-infection of 
Huh-7 hepatoma cells, and showed for the first time that this process can be 
markedly reduced by entry receptor inhibition and antibody neutralisation. Moreover, 
heat-killed lymphocytes were still able to transmit infection to hepatomas albeit at a 
reduced efficiency, revealing that there are passive and active elements of trans-
infection in operation. The actin cytoskeleton also plays a significant, but 
incompletely defined role in trans-infection. We have found no evidence for 
lymphocyte uptake by hepatoma cells having an effect on trans-infection, although 
further studies are necessary in order to provide new insights into this potentially 
significant mode of HCV transmission.  
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ABSTRACT 
Neutrophil recruitment to inflamed tissue is a crucial process in the immune system’s 
defense against infection and inflammation. Mesenchymal stem cells (MSC) found in 
the surrounding tissue stroma are normally immunosuppressive, and have recently 
been shown to reduce neutrophil adhesion to inflamed macrovascular endothelium. 
However, there is evidence to suggest that MSC may become immunostimulatory in 
chronically inflamed tissue, such as that found in autoimmune disease. This project 
aimed to (i) characterise neutrophil recruitment to the more physiologically relevant 
microvascular endothelium, (ii) examine whether MSC could suppress this process, 
and (iii) find out how MSC phenotype may change on prolonged exposure to pro-
inflammatory cytokines. We found that micro- and macrovascular endothelium 
supported neutrophil adhesion equally well in vitro, but we did not observe 
suppression of neutrophil recruitment in the presence of MSC. Upon prolonged 
stimulation with transforming growth factor β (TGFβ) under low-serum conditions, 
MSC surface marker expression was altered, which could indicate a phenotypic shift 
or differentiation. Further studies of MSC phenotype changes in inflammatory 
conditions, and how they may affect neutrophil recruitment to vascular endothelium, 
may help shed light on the complex cellular interactions within chronically inflamed 
tissue. 
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1. INTRODUCTION 
 
White blood cells (leukocytes) need to undergo successful extravasation from the 
blood into target tissue in order to defend the host from infection and inflammation. 
Neutrophils are among the first to get recruited; their abundance and crucial role in 
phagocytosing invading pathogens makes them a key component of the innate 
immune system (Johnson-Léger et al. 2000). The recruitment of neutrophils to the 
vascular endothelium consists of a series of tightly regulated steps collectively known 
as the leukocyte adhesion cascade (Ley et al. 2007). This process, and the fate of 
neutrophils once inside the target tissue, is influenced by the state of the recruiting 
endothelium as much as by its stromal microenvironment. Crosstalk between 
vascular endothelial cells (EC) and stromal cells (such as fibroblasts and 
mesenchymal stem cells) influences EC phenotype and, as a result, modulates their 
ability to support neutrophil recruitment (e.g. reviewed by McGettrick et al. 2012). In 
particular, mesenchymal stem cells (MSC) have recently been shown to down-
regulate the adhesion of neutrophils to inflamed endothelium in vitro (Luu et al. 
2013). However, exposure to a chronic inflammatory milieu, such as the one found in 
inflammatory and autoimmune diseases, can cause the MSC phenotype to shift 
towards immune stimulation rather than suppression (El-Jawhari et al. 2014). While 
the immunosuppressive and anti-inflammatory properties of MSC have been the 
focus of much research, little is known about how their phenotype may change in 
response to the conditions in the surrounding stroma, or the impact this may have on 
neutrophil recruitment to the endothelium. This project will therefore aim to be one of 
the first to address these important questions. 
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1.1 Neutrophil recruitment to vascular endothelium 
Neutrophils are generated in the bone marrow, and circulate in the bloodstream for 
several hours before being recruited to sites of infection, inflammation or injury. They 
are the first leukocytes to appear in inflamed tissue, their primary role being 
elimination of microbes and ingestion of cell debris by phagocytosis (Springer 1995; 
Zarbock & Ley 2008). Their importance is perhaps most strikingly demonstrated by 
individuals suffering from leukocyte adhesion deficiency (LAD), a disorder in which 
neutrophils fail to accumulate at sites of inflammation. People with LAD suffer from 
recurrent bacterial infections that, if left untreated, often prove fatal (Anderson & 
Springer 1987; Johnson-Léger et al. 2000; Zarbock & Ley 2008). 
 
The first prerequisite for neutrophil recruitment is the presence of pro-inflammatory 
signals in the target tissue that activate the local vascular endothelium, rendering it 
capable of attracting circulating leukocytes (Springer 1995). Depending on shear 
stress and interactions with other blood cells, leukocytes will eventually flow closer to 
endothelial surface rather than in the centre of the blood vessel – a process referred 
to as margination. The bulk of neutrophil adhesion to the endothelium happens in 
postcapillary venules, where margination is enhanced due to shear stress being low 
enough to support attachment (Springer 1995; Langer & Chavakis 2009). The 
recruitment process continues in a sequence of well-documented steps known as the 
adhesion cascade, of which neutrophil rolling, activation, arrest and transendothelial 
migration are the major stages (Ley et al. 2007). Recently it was found that the 
basement membrane deposited by the endothelium represents an additional barrier 
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that neutrophils need to overcome before being able to gain access to tissue 
interstitium (Burton et al. 2011).  
 
1.1.1 Adhesion cascade and the signalling molecules involved 
Activation of the vascular endothelium by thrombin, histamine or pro-inflammatory 
cytokines such as TNFα and IL-1β results in endothelial expression of E- and P-
selectin (Springer 1995; Sanz & Kubes 2012). These glycoproteins facilitate the initial 
tethering and rolling of neutrophils by binding to their counter-receptors on the 
neutrophil surface, namely P-selectin glycoprotein ligand-1 (PSGL-1), E-selectin 
ligand-1 (ESL-1) and CD44. Another molecule with a role in neutrophil capture and 
rolling is L-selectin, also expressed on the surface of neutrophils (Springer 1995; 
Williams et al. 2011). The importance of selectins in the adhesion cascade has been 
well-established in both in vitro and in vivo studies. For example, concurrent antibody 
blockade of E- and P-selectin significantly decreased capture of neutrophils on 
TNFα-treated human umbilical vein endothelial cells (HUVEC), although this 
decrease was not observed in IL-1β-treated endothelium (Sheikh et al. 2005). In vivo, 
P-selectin-/- mice exhibited increased numbers of circulating neutrophils and delayed 
neutrophil recruitment to inflamed tissue (Mayadas et al. 1993). In another study 
which employed antibody blockade of P- and L-selectin in wild-type or P- and L-
selectin-/- mice, it was concluded that P-selectin was necessary for the initial stages of 
rolling, while L-selectin mediated most of it at later time-points. Interestingly, and in 
contrast to the in vitro studies on human tissue referred to above, evidence could not 
be found for E-selectin involvement in leukocyte rolling in mice (Ley et al. 1995). 
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While rolling, neutrophils come into contact with chemokines presented by 
glycosaminoglycans (GAGs) on the endothelial luminal membrane. The chemokines 
which selectively interact with neutrophils include CXCL1, CXCL2, and CXCL5; all of 
them bind to their common G-protein coupled receptor (GPCR) on the neutrophil 
surface, CXCR2 (Sanz & Kubes 2012). Functional blockade of any of these through 
the use of neutralising antibodies has effectively reduced neutrophil adhesion to 
inflamed microvasculature in vivo (Nabah et al. 2004; Duchene et al. 2007; Coelho et 
al. 2008). Chemokine engagement of their neutrophil GPCRs leads to “inside-out” 
signalling, resulting in the activation of β2 integrins expressed on neutrophil surface. 
Activated integrins cluster together and undergo a conformational change from bent, 
inactive to fully extended, active form with high binding affinity (Luo et al. 2007). This 
enables them to bind to their corresponding ligands on the endothelium which, for β2 
integrins, is the intercellular adhesion molecule-1 (ICAM-1). This in turn causes 
stable adhesion and arrest of neutrophils on the vascular endothelium (Luo et al. 
2007).  
 
Integrins are also responsible for transferring signals from extracellular space into the 
neutrophils themselves (“outside-in” signalling). Adhesion is strengthened further as 
a consequence, leading to leukocyte flattening and crawling across the endothelial 
surface in search of a preferred site to migrate across (Ley et al. 2007; Sanz & Kubes 
2012). While initial neutrophil adhesion is mediated by the αLβ2 integrin, intraluminal 
crawling is instead mediated by the αMβ2 integrin via its interaction with ICAM-1 (Ley 
et al. 2007). This was elucidated through intravital and confocal microscopy of 
inflamed microvessels in wild-type as well as αLβ2
-/- and αMβ2  
-/- mice, where αLβ2
-/- 
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neutrophils showed very little adhesion and αMβ2
-/- neutrophils crawled much less 
once adhered (Phillipson et al. 2006). 
 
In a recent in vitro study, neutrophils were shown to need an additional stimulus 
before they can migrate across the endothelium (Tull et al. 2009). This is supplied in 
the form of a lipid signal, prostaglandin-D2 (PGD2), generated from metabolism of 
arachidonic acid by cyclooxygenase (COX) enzymes. When an alternative dietary 
fatty acid was metabolised by COX to PGD3 instead, this was found to antagonise 
the PGD2 receptor and lead to inhibition of neutrophil migration across TNFα-
stimulated endothelial cells (Tull et al. 2009). Once activation by chemokines and 
PGD2 signalling, in that order, have taken place, neutrophils can cross the 
endothelium by interacting with molecules including ICAM-1, platelet-endothelial cell 
adhesion molecule-1 (PECAM-1), junctional adhesion molecule-A (JAM-A) and CD99 
(Ley et al. 2007; Sanz & Kubes 2012). Reduced neutrophil infiltration into tissue has 
been observed in both PECAM-1-/- (Schenkel et al. 2004) and JAM-A-/- mice (Corada 
et al. 2005; Khandoga et al. 2005), providing evidence for their role in transmigration. 
Neutrophils transmigrate either through endothelial cell junctions (paracellular route) 
or, less commonly, through the body of the EC (transcellular route) (Ley et al. 2007). 
Several in vitro studies on both primary EC and endothelial cell lines have concluded 
that leukocytes overwhelmingly cross the endothelium via the paracellular route 
(Engelhardt & Wolburg 2004). A recent in vivo study supported this by using intravital 
microscopy to show that leukocytes transmigrated at tricellular junctional regions of 
the endothelium, of which a significant proportion were ICAM-1 enriched (Sumagin & 
Sarelius 2010). However, in vivo migration across the blood-brain barrier (BBB) has 
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been shown to happen invariably via the transcellular route (Engelhardt & Wolburg 
2004). Imaging evidence has also been produced of neutrophils crossing the skin 
endothelium in a transcellular manner, i.e. through the body of the EC, when they 
have been stimulated with a chemoattractant (Feng et al. 1998). The data on which 
route neutrophils normally take in the body in order to transmigrate is therefore likely 
to be context-dependent. 
 
The final stage of neutrophil migration into tissue is the migration across the EC 
basement membrane (BM) – a process found to be β3 integrin-dependent (Burton et 
al. 2011) – and through the pericyte sheath (Ley et al. 2007) in order to gain access 
to tissue stroma. Crosstalk between EC and tissue stromal cells can modulate the 
state of the endothelium, thus changing the extent to and the way in which 
neutrophils are recruited in the first place (McGettrick et al. 2012). This modulation 
becomes even more important in disease states characterised by chronic 
inflammation, where stromal cells may undergo phenotypic alterations that support 
excessive neutrophil infiltration and thus contribute towards inflammatory disease 
pathology. 
 
1.2 The influence of the stromal microenvironment on neutrophil 
adhesion 
Neutrophil (and, more generally, leukocyte) recruitment to the endothelium is a 
crucial part of physiological inflammation, which is necessary in order to clear 
infection and repair damaged tissue. The process requires controlled leukocyte entry 
into and clearance from the target tissue to be successful. Dysregulated, persistent 
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infiltration of leukocytes leads to tissue damage and chronic inflammation, which form 
the pathological basis of many autoimmune and inflammatory diseases such as 
rheumatoid arthritis (RA) (McGettrick et al. 2012). 
 
In the past decade, a hypothesis has emerged that leukocyte recruitment patterns to 
different tissues are strongly influenced by the local EC microenvironment. EC exist 
in close proximity to various cells of the tissue stroma, such as smooth muscle cells 
(SMC), pericytes and fibroblasts, all of which are capable of conditioning endothelial 
responses and therefore leukocyte adhesion to EC (Nash et al. 2004) (Figure 1). 
The evidence that eventually confirmed this hypothesis can be neatly traced using 
the example of fibroblasts. These stromal cells normally provide tissue structural 
support (Nash et al. 2004). However, an early in vitro study found that soluble factors 
secreted by human skin fibroblasts were able to change the shape and organisation 
of animal-derived EC when the two were co-cultured in collagen gels (Kuzuya & 
Kinsella 1994). It was later shown that fibroblasts originating from different tissues – 
namely skin, inflamed synovium and lymphoid tissue – showed markedly different 
gene expression in response to pro-inflammatory stimuli such as TNFα (Parsonage 
et al. 2003). Skin and synovial fibroblasts also differed in the patterns and amounts of 
cytokines they secreted in response, indicating that inflammatory reactions, in which 
they seem to play an active part, were tissue-specific (Parsonage et al. 2003). The 
studies that followed established a difference between fibroblasts originating from 
healthy and those coming from diseased tissue in their effect on the endothelium. 
“Healthy” fibroblasts were able to maintain the vascular endothelium in a resting state 
and prevent excessive leukocyte infiltration. Conversely, those found in diseased 
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tissues, such as the rheumatoid joint, were imprinted with a pro-inflammatory 
phenotype which further stimulated inappropriate leukocyte recruitment (McGettrick 
et al. 2009; McGettrick et al. 2012). Neutrophil recruitment was mediated by P- and 
E-selectin, β2 integrins, CXCR2 and its ligand CXCL5, as evidenced by antibody 
neutralisation of these molecules which reduced or abolished neutrophil adhesion 
(Lally et al. 2005; Smith et al. 2008). CXCL5 was fibroblast-derived and transported 
to the endothelial surface in order to activate neutrophils (Smith et al. 2008). This 
finding provided an example of how EC-stromal crosstalk can promote inflammation; 
in this case, the pro-inflammatory fibroblast phenotype translated to the endothelium 
in the form of chemokine expression. 
 
Naturally, other components of the stroma, such as the BM and the SMC, can also 
modulate endothelial phenotype and consequently neutrophil recruitment in both 
health and disease (McGettrick et al. 2012), although these will not be discussed 
here. On the whole, it is clear that in conditions such as RA – the most common 
autoimmune joint disease – the stroma takes an active role in mediating dysregulated 
leukocyte adhesion. Understanding the mechanisms by which this happens is crucial 
to finding a way to switch off excessive inflammation and help treat this debilitating 
condition. A recent review highlighted the possibility that mesenchymal stem cells 
(MSC) resident in the synovium may be capable of suppressing exaggerated immune 
responses mediated by other stromal cells including fibroblasts (El-Jawhari et al. 
2014). This provides an exciting avenue for further research into the ability of MSC to 
modulate leukocyte, and more specifically neutrophil, recruitment to the endothelium. 
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Figure 1 – Neutrophil adhesion cascade and its interactions with tissue stromal cells. 
Activated vascular endothelium expresses selectins, which mediate neutrophil capture from 
flow and their rolling across endothelial surface. Subsequent expression of endothelial-
derived chemokines, or transcellular transportation of stromal cell-derived chemokines to the 
endothelial surface, stabilises neutrophil adhesion. This activates β2 integrins on neutrophil 
surface, which interact with endothelial ICAM-1 to mediate arrest of the leukocytes. Once 
neutrophils receive the PGD2 signal, they can cross the endothelium by binding to junctional 
molecules such as JAMs. Subendothelial crawling is mediated by a combination of β1 and β2 
integrins, while crossing of the basement membrane is β3 integrin-dependent. Once inside 
the tissue, neutrophils may be directed to the site of inflammation by chemotactic gradients 
generated by stromal cells.  
Adapted from McGettrick et al. 2012.   
Stromal cells 
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1.3 Mesenchymal stem cells as modulators of neutrophil recruitment 
MSC are multipotent, fibroblastic-like stromal progenitor cells capable of self-renewal 
and differentiation into multiple cell types of the mesodermal lineage (Krampera 
2011; Tyndall 2014) (Figure 2). These characteristics mean that MSC have 
persistently generated great interest among researchers, but different investigators 
have reported using vastly different approaches to their isolation, expansion and 
characterisation. In an attempt to standardise the use of these cells and thus render 
varied study outcomes comparable, the International Society for Cellular Therapy has 
proposed three minimal criteria for the definition of human MSC (Dominici et al. 
2006). They must: (i) adhere to plastic in standard cell culture; (ii) express CD73, 
CD90 and CD105 while lacking expression of haematopoietic markers (including 
CD14, CD34 and CD45) and major histocompatibility complex (MHC) class II surface 
molecules; and (iii) be capable of differentiating into osteoblasts, chondroblasts and 
adipocytes in vitro (Dominici et al. 2006).  
 
Numerous studies carried out over the years, both in animal models and as part of 
human clinical trials, have demonstrated that infused MSC homed to injured tissue 
and induced its repair. However, it became increasingly apparent that they were able 
to bring about functional improvement without actual target tissue engraftment or 
even differentiation (Prockop 2009; Waterman et al. 2010). For example, when 
human bone marrow-derived MSC were injected into immunodeficient mice with 
acute myocardial infarction, cardiac function and fibrosis significantly improved 
without apparent MSC engraftment into cardiac tissue (Iso et al. 2007). This and 
other studies pointed to the possibility that, in fact, immunomodulation by MSC via 
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paracrine signals and cell-to-cell contacts was taking place in the target tissue. Not 
only that, but it was proposed that MSC were activated by crosstalk with their 
microenvironment to secrete cytokines, chemokines and other factors that were 
specifically adapted to the tissue in question (Prockop 2009). 
 
The immunomodulatory capacity of MSC has since been extensively studied in 
relation to cells of both adaptive and innate immune system, including T- and B-
lymphocytes, natural killer (NK) cells and dendritic cells. MSC exerted anti-
proliferative effects on B-cells and NK-cells through the secretion of, among other 
factors, prostaglandin E2 (PGE2) and transforming growth factor β (TGFβ). They were 
also able to induce apoptosis of activated T-cells via the action of indoleamine 2,3-
dioxygenase (IDO) (Koh & Kang 2012). Comparatively fewer studies looked at MSC 
effects on neutrophils. One of them found that, when MSC from healthy donors were 
cultured with freshly isolated neutrophils in vitro, they significantly inhibited apoptosis 
of both resting and activated neutrophils via the secretion of soluble factors. Antibody 
blockade determined that the relevant anti-apoptotic factor was interleukin-6 (IL-6) 
(Raffaghello et al. 2008). This study, however, focused on replicating the bone 
marrow niche and consequently did not look at the effects of MSC in inflamed tissue. 
In fact, our group was the first to show that MSC, like other stromal cells, are capable 
of modulating leukocyte recruitment to inflamed endothelium via actions on the EC 
themselves (Luu et al. 2013). When brought together in co-culture in vitro, MSC and 
HUVEC supported markedly lower levels of neutrophil adhesion compared to 
HUVEC monoculture when both were stimulated with either TNFα or IL-1β. 
Furthermore, MSC-derived IL-6 was detected as the soluble factor responsible for 
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this decrease in recruitment, contrary to its more established role as a pro-
inflammatory cytokine; when IL-6 was neutralised using an antibody, the anti-
inflammatory effects of co-culture were lost (Luu et al. 2013) (Figure 3). 
 
The immunomodulation capabilities of MSC quickly led to them being explored for 
therapeutic potential in RA, where apart from excessive leukocyte infiltration, 
dysregulated fibroblast activation contributed to joint destruction (Bottini & Firestein 
2013). MSC were found to be modulated by pro-inflammatory cytokines such as 
TNFα or IL‐1β which were present in the inflamed microenvironment, a process 
referred to as ‘licensing’ (Krampera 2011). This in turn caused them to increase the 
production of chemokines and inducible nitric oxide synthase (iNOS) which drove 
immunosuppression, as evidenced by their immunosuppressive effect being 
abolished in vitro by chemokine receptor blockade or in MSC derived from iNOS-/- 
mice (Ren et al. 2008). However, this finding was in conflict with the results from an 
earlier in vivo study, where MSC injected into mice with collagen-induced arthritis (a 
murine model of RA) conferred no therapeutic benefit. In fact, their 
immunosuppressive capability was reversed by subsequently adding TNFα to them 
in vitro (Djouad et al. 2005). While both studies looked at MSC effects on T-cell 
proliferation rather than neutrophil recruitment, it became clear that the local 
environment could influence MSC phenotype and consequently their anti-
inflammatory properties. In particular, the activation of Toll-like receptors (TLRs) on 
the surface of MSC was recently found to differentially polarise them towards a pro- 
(MSC1) or anti-inflammatory (MSC2) phenotype. TLR4 stimulation caused pro-
inflammatory cytokines such as IL-6, IL-8 or TGFβ to be produced, while TLR3 
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activation induced the secretion of IDO and therefore rendered the cells 
immunosuppressive (Waterman et al. 2010). All of the above provided evidence that, 
while they may normally be able to suppress immune responses, MSC function is 
likely to shift towards immune stimulation in a chronically inflamed milieu such as that 
found in RA (El-Jawhari et al. 2014). 
 
Taking the available evidence into account, we propose to lead the study of the 
immunomodulatory properties of MSC in a new direction. Recent findings using a 
mouse model of cartilage destruction (Croft et al. n.d., unpublished data) suggested 
that, in the inflamed synovium of RA, fibroblasts were able to differentiate into two 
distinct subsets. Those found in the lining expressed GP38, displayed a more 
aggressive, migratory phenotype and mediated cartilage degradation. Conversely, 
fibroblasts in the sub-lining (and therefore further away from the cartilage) expressed 
CD248 and were not migratory, suggesting they had a role in regulation rather than 
invasion. GP38 expression could be induced in cell culture by stimulating RA 
synovial fibroblasts (RASF) with TNFα, which in turn mediated cartilage destruction. 
Stimulating them with TGF1, on the other hand, induced expression of CD248 and 
reduced in vitro degradation of cartilage (Croft et al. n.d., unpublished data). 
Considering MSC share a lot of their characteristics with fibroblasts (Haniffa et al. 
2009), and in view of their immunomodulatory capacity, it would be interesting to see 
whether stimulation of MSC with the above cytokines resulted in similar changes in 
surface expression and phenotype. Furthermore, the study of the effect this would 
have on MSC:EC co-culture and subsequent neutrophil recruitment to the 
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endothelium would provide very useful additional insights into the regulation of the 
immune response by MSC in chronic inflammation. 
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Figure 2 – The multipotentiality of MSC. 
MSC are capable of self-renewal in the bone-marrow cavity, as well as differentiation 
towards cells of the mesodermal lineage. Their reported ability to transdifferentiate into cells 
of other lineages (ecto- and endoderm) is controversial in vivo.  
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Immunology 
(Uccelli et al. 2008), copyright © Macmillan Publishers Limited (2008) 
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Figure 3 – The immunomodulatory capabilities of MSC. 
MSC can exert their immunosuppressive effects on cells of both innate and adaptive immune 
system via the secretion of different chemokines and soluble factors. They can induce 
expansion of immunosuppressive Treg cells as well as apoptosis of activated T-cells by 
secreting human leukocyte antigen-G5 (HLA-G5) and IDO respectively. They are also 
capable of inhibiting NK-cell and B-cell proliferation through the actions of PGE2 and TGFβ, 
and can suppress DC differentiation via the action of, among other factors, IL-6 and IL-10. 
Most recently, MSC have been shown to suppress neutrophil adhesion and transendothelial 
migration by acting on the vascular endothelium, which in turn supported less neutrophil 
recruitment; this effect was also found to be mediated by IL-6. 
Adapted from: The pro-metastatic role of bone marrow-derived cells: a focus on MSCs and 
regulatory T cells. Koh, B.I. & Kang, Y. EMBO Reports, 13(5). Copyright © 2012 European 
Molecular Biology Organization 
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1.4 Hypothesis and aims 
We hypothesise that MSC exposed to pro-inflammatory cytokines, such as TNFα, for 
several days prior to co-culture with EC acquire an immunostimulatory phenotype, 
thus causing significantly greater neutrophil adhesion levels to those seen in normal 
co-culture conditions.  
 
The main aims of the project are: 
- To characterise neutrophil recruitment to cytokine-stimulated dermal microvascular 
endothelial cells (DMEC), which may be a more representative model of in vivo 
neutrophil recruitment than HUVEC; 
- To compare the effects of MSC on neutrophil adhesion to cytokine-stimulated 
HUVEC and DMEC; 
- To assess the effects of prolonged cytokine treatment (TNFα and TGFβ) on MSC 
phenotype, specifically focusing on surface expression of GP38, CD248 and MSC 
surface markers CD73 and CD90.  
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2. MATERIALS AND METHODS 
 
2.1 Isolation and culture of EC and MSC 
HUVEC were isolated as described previously (Cooke et al. 1993) from umbilical 
cords obtained from the Human Biomaterials Resource Centre (University of 
Birmingham, UK) following informed consent. The cells were cultured in Medium 199 
(M199; Gibco Invitrogen Compounds, Paisley, Scotland, UK) supplemented with 20% 
foetal calf serum (FCS), 35µg/ml gentamycin sulphate, 10ng/ml epidermal growth 
factor (EGF), 1µg/ml hydrocortisone (all Sigma-Aldrich, Poole, UK) and 2.5µg/ml 
amphotericin B (Gibco Invitrogen Compounds). HUVEC were used at passage 1. 
 
DMEC were obtained from PromoCell and cultured in endothelial cell growth medium 
MV supplemented with 5% FCS, 0.4% endothelial cell growth supplement (ECGS, 
bovine hypothalamic extract), 10ng/ml EGF, 90µg/ml heparin and 1µg/ml 
hydrocortisone (all PromoCell GmbH, Heidelberg, Germany). DMEC were used at 
passage 4. 
 
Human bone marrow-derived MSC (BMMSC), purchased from Lonza, were cultured 
in MSCGM™ Mesenchymal Stem Cell Growth Medium BulletKit as recommended by 
the manufacturer (Lonza Ltd, Basel, Switzerland). BMMSC were expanded by three-
way splits and used between 3rd and 5th passages. 
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2.2 Isolation of neutrophils 
Following informed consent, blood was obtained by venepuncture from healthy 
volunteers and collected into ethylenediaminetetraacetic acid (EDTA)-coated tubes 
(Sarstedt Ltd, Leicester, UK). Neutrophils were isolated by overlaying whole blood on 
density gradients of Histopaque 1077 above Histopaque 1119 (both Sigma-Aldrich) 
and centrifuging at 800g for 30 minutes (Figure 4). The neutrophil fraction was 
harvested and washed twice by spinning at 250g for 5 minutes and re-suspending in 
phosphate-buffered saline (PBS; Sigma-Aldrich) containing 1mM Ca2+, 0.5mM Mg2+ 
and 0.15% bovine serum albumin (BSA; Gibco; PBS/BSA). Neutrophils were counted 
using a Z2 Coulter Particle Count & Size Analyzer (Beckman Coulter Ltd, High 
Wycombe, UK) and diluted with PBS/BSA to a final concentration of 1x106 cells/ml. 
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Figure 4 – Neutrophil isolation using the Histopaque density gradient. 
Whole blood was overlayed on the density gradient of Histopaque 1077 (H1077) over 
Histopaque 1119 (H1119) and centrifuged at 800g for 30 minutes to give the separation of 
blood components as shown above. Plasma and the upper cell band containing mononuclear 
cells and platelets were removed before harvesting neutrophils from the lower band. 
Neutrophils were washed twice and re-suspended in the correct volume of PBS/BSA to give 
1x106 cells/ml. 
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2.3 Seeding of EC monoculture and MSC:EC co-culture 
Confluent flasks of HUVEC and DMEC were rinsed with 0.02% EDTA for 2 minutes 
before dislodging the cells using 0.25% trypsin (both Sigma-Aldrich) in a 2:1 ratio 
with EDTA. Serum-containing neutralising medium was added before centrifuging at 
250g for 5 minutes. HUVEC were re-suspended in MSCGM (BMMSC culture medium 
containing 10% FCS), and DMEC in DMEC culture medium with or without 
hydrocortisone. Endothelial cells were then seeded into µ-slide VI channel slides 
(ibidi GmbH, Martinsried, Germany) at a seeding density designed to give confluent 
monocultures in 24h (Luu et al. 2013). 
 
For MSC:EC co-culture, flasks of BMMSC were treated with EDTA and trypsin as 
above and MSC were resuspended in serum-free rather than complete (10%) 
MSCGM. MSC were labelled with 5 µM Cell Tracker Green (Life Technologies Ltd, 
Paisley, UK) for one hour, with serum-free medium being replaced by complete 
medium halfway through to avoid cell starvation. MSC were then counted using a 
Cellometer (Nexcelom Bioscience, Lawrence, Massachusetts, USA) and adjusted to 
a final concentration of 1.5x105 cells/ml before being added to the ibidi channel slides 
containing confluent EC monolayers (Luu et al. 2013). After 60-90 minutes, non-
adherent MSC were washed off and the rest were allowed to incorporate into the 
monolayer for 24h. 
 
After 24h, mono- and co-cultures were treated with TNF-α (0, 1, 10 or 100 U/ml) or 
IL-1β (5x10-9 g/ml) (both Sigma-Aldrich) for 4h before being attached to the flow-
based adhesion assay system (section 2.4). 
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2.4 Flow-based adhesion assay 
The flow system was assembled as described previously (McGettrick et al. 2007) 
(Figure 5). Plastic tubing was used to attach ibidi channel slides to the flow 
apparatus which was enclosed in a temperature-controlled chamber at 37°C and 
linked to a fluorescent video-microscope. PBS/BSA was used to wash the system for 
2 minutes. Neutrophils were then perfused over EC or MSC:EC monolayers at a wall 
shear stress of 0.05Pa and flow rate of 0.4ml/min for 4 minutes. This was followed by 
a second washout period, during which digitised recordings were taken of ten 
random fields along the centre of the flow channel at 2 and 9 minutes relative to end 
of neutrophil bolus. A 5-minute recording of a separate single microscope field was 
also made to analyse the migration of neutrophils under the endothelium. In addition, 
matched phase-contrast and fluorescent images were taken of channels containing 
MSC in order to visualise MSC integration into the EC monolayer and calculate the 
MSC:EC ratio (Figure 6). Images were analysed offline using ImagePro analysis 
software (DataCell Limited, Finchampstead, UK).  
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Figure 5 – Schematic of the flow-based adhesion assay system. 
Ibidi channel slides were placed within an enclosed flow chamber set at a constant 
temperature of 37°C. A syringe pump was used to pull the neutrophils from the sample 
reservoir and allow them to flow over the cell monolayers within the channels at a flow rate of 
0.4ml/min. A cell-free wash buffer (PBS/BSA) contained within the wash reservoir was run 
before and after the 4-minute neutrophil bolus. Images and recordings were captured live 
and visualised on the monitor using ImagePro software. 
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Figure 6 – Representative video-microscope image of MSC:EC co-culture. 
DMEC were seeded into ibidi channel slides such that they would yield a confluent 
monolayer within 24h. MSC labelled with Cell Tracker Green were then added to the same 
channel slides and allowed to incorporate for a further 24h. The co-cultures were treated with 
TNFα for 4h before being exposed to neutrophil flow. Following the flow-based adhesion 
assay, four matched phase-contrast and fluorescent images were taken down the centre of 
each channel using x10 magnification. EC were counted from phase-contrast, and labelled 
MSC from fluorescent images to determine MSC:EC ratio.  
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2.5 Image analysis 
Adherent neutrophils were classified as: 
a) Rolling – spherical cells moving fast across the endothelium, but more slowly 
than free-flowing neutrophils; 
b) Stationary – spherical or cells of distorted shape firmly adhering to the 
endothelium or oscillating slightly around their position; 
c) Migrated – phase-dark cells of various shapes that have crossed the 
endothelium and typically migrate away from their point of entry once 
underneath. 
The number of neutrophils in each classification and the total number of adherent 
neutrophils were averaged from the ten microscope fields per channel and converted 
to number/mm2/106 perfused. Rolling and migration velocities were also obtained by 
tracking the movement of rolling and transmigrated cells and finding the average 
distance travelled from ten cells in each category. The velocities were then 
expressed in µm/s (rolling) and µm/min (migration). In co-cultures, the calculated 
number of EC and MSC per channel was used to determine the MSC:EC ratio. 
 
2.6 Preparation and labelling of MSC for flow cytometry 
BMMSC were dissociated from the flask using EDTA and trypsin as described in 
section 2.3 and seeded into 12-well plates at the seeding density of 7-10,000 
cells/well for 24h. Some wells were incubated in low-serum (2%) BMMSC medium for 
6h, after which MSC in both complete and low-serum media were treated with 
100U/ml TNF-α or 10ng/ml TGF-β1 (PeproTech, Rocky Hill, New Jersey, USA) for 4-
6 days. MSC were then lifted from the wells using accutase (Gibco) in order to 
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preserve surface marker expression, centrifuged at 250g for 5 minutes and 
resuspended in PBS/BSA. The cells were subsequently labelled with antibodies 
listed in Table 1, washed with PBS/BSA and fixed with 2% paraformaldehyde 
(Sigma-Aldrich). Samples were analysed in a FACS Analyser (CyAn ADP, 
DakoCytomation, Glostrup, Denmark) and the fluorescence data obtained using 
Summit 4.3 software. Data were expressed as mean fluorescence intensities (MFI) 
and percentages of positive fluorescing cells of each sample. 
 
2.7 Statistical analysis 
All data were analysed using GraphPad Prism 5 and expressed as mean ± standard 
error of the mean (SEM). Analysis of variance (ANOVA) was used to assess variation 
between multiple conditions, while Bonferroni post-tests compared individual 
treatments, as appropriate. Statistical significance was assumed if P < 0.05. Where 
ANOVA did not show statistical significance for any of the parameters, no mention of 
it was made in the figure legends. 
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Table 1 – List of antibodies used to label MSC for surface expression of GP38, CD248 
and MSC positive surface markers CD73 and CD90 
 
Antibody Clone Conjugated dye Manufacturer 
Anti-Human Podoplanin 
(GP38) 
NZ-1.3 PE 
eBioscience Inc, 
San Diego, 
California, USA 
Rat IgG2a Isotype 
Control for Anti-Human 
Podoplanin (GP38) 
eBR2a PE " 
Mouse Anti-Human 
CD248  
B135.1, 
10x 
Unconjugated (requires 2° 
antibody)  
In-house 
antibody 
Goat Anti-Mouse IgG 
(2° antibody to Mouse 
Anti-Human CD248) 
1010-02 FITC 
SouthernBiotech, 
Birmingham, 
Alabama, USA 
Mouse Anti-Human 
CD73 
AD2 FITC 
BD Biosciences 
– Pharmingen, 
San Diego, 
California, USA 
Mouse Anti-Human 
CD90 
5E10 Brilliant Violet™ 421 " 
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3. RESULTS 
 
3.1 Neutrophil recruitment to TNF-α treated DMEC is dose-dependent 
The studies of neutrophil recruitment have overwhelmingly been performed on 
HUVEC, with very little known about how DMEC support this process. Being of 
micro- rather than macrovascular origin, DMEC are potentially more representative of 
the endothelium neutrophils encounter in vivo, where the vast majority of adhesion 
happens in microvessels. To address this, we investigated the ability of TNFα-
stimulated DMEC to support neutrophil recruitment. DMEC monocultures were either 
left untreated or were treated with 1, 10 or 100U/ml TNFα for 4h before being 
exposed to a flow of neutrophils. We observed a dose-dependent increase in 
neutrophil recruitment (Figure 7), with adhesion remaining reasonably stable over 
the course of the assay. Transendothelial migration was significantly higher at 
100U/ml compared to 10U/ml TNFα, where most of the neutrophils were firmly 
adherent on the DMEC surface. Behaviour was not determined for 1U/ml TNFα as 
neutrophil adhesion was too low (Figure 8). 
 
From the results above we concluded that DMEC were able to support neutrophil 
recruitment in a TNFα dose-dependent manner, supporting the observations made in 
HUVEC in previous studies (e.g. Luu et al. 2013).   
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Figure 7 – Effect of TNFα concentration on neutrophil recruitment to DMEC from flow. 
DMEC monocultures were stimulated with TNFα for 4h before being exposed to a flow of 
neutrophils (1x106/ml) at a rate of 0.4ml/min for 4 minutes. The total number of adhering 
neutrophils was expressed as neutrophils/mm2/106 cells perfused and determined at 2 and 9 
minutes after neutrophil flow stopped. Two-way ANOVA showed a significant effect of TNFα 
concentration (P<0.0001), but not time, on neutrophil adhesion. *** = P<0.001 for comparison 
of 100U/ml TNFα to each of the other TNFα concentrations by Bonferroni post-tests. Data 
are mean ± SEM, n=4. 
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Figure 8 – Effect of TNFα concentration on the behaviour of neutrophils recruited to 
DMEC from flow. 
DMEC monocultures were stimulated with TNFα for 4h before being exposed to a flow of 
neutrophils (1x106/ml) at a rate of 0.4ml/min for 4 minutes. Rolling, stationary and migrated 
neutrophils were analysed at (A) 2 and (B) 9 minutes after neutrophil flow stopped, and each 
expressed as a percentage of total adherent cells. Two-way ANOVA showed a significant 
effect of neutrophil behaviour (P<0.001), but not TNFα concentration, on % adherent 
neutrophils. ** = P<0.01 and *** = P<0.001 for comparison of 10U/ml to 100U/ml TNFα by 
Bonferroni post-tests. Data are mean ± SEM, n=4. 
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3.2 TNFα and IL-1β stimulation of DMEC result in similar neutrophil 
adhesion and behaviour 
In previous studies using HUVEC, comparable neutrophil recruitment and behaviour 
were observed for endothelial stimulation with TNFα or IL-1β (Sheikh et al. 2005). We 
wished to examine whether the same held true for DMEC. We therefore stimulated 
DMEC monocultures with high-dose TNFα (100U/ml) or IL-1β (5x10-9 g/ml) for 4h 
before perfusing neutrophils over them. Total neutrophil adhesion levels were very 
similar with both cytokines (Figure 9). Neutrophil behaviour was also analogous, with 
stationary neutrophil numbers decreasing in favour of migrated neutrophils over time 
(Figure 10). Rolling and migration velocities were compared as well (Figure 11). 
From two separate experiments, we noticed a tendency for neutrophils to roll more 
quickly and migrate more slowly on TNFα-stimulated compared to IL-1β-treated 
DMEC. However, further experiments are required to determine whether this is 
statistically significant. 
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Figure 9 – Comparison of the effect of TNFα and IL-1β on neutrophil recruitment to 
DMEC from flow. 
DMEC monocultures were stimulated with 100U/ml TNFα or 5x10-9g/ml IL-1β for 4h before 
being exposed to a flow of neutrophils (1x106/ml) at a rate of 0.4ml/min for 4 minutes. The 
total number of adhering neutrophils was expressed as neutrophils/mm2/106 cells perfused 
and determined at 2 and 9 minutes after neutrophil flow stopped. Data are mean ± SEM, 
n=2. 
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Figure 10 – Comparison of the effect of TNFα and IL-1β on the behaviour of 
neutrophils recruited to DMEC from flow. 
DMEC monocultures were stimulated with 100U/ml TNFα or 5x10-9 g/ml IL-1β for 4h before 
being exposed to a flow of neutrophils (1x106/ml) at a rate of 0.4ml/min for 4 minutes. Rolling, 
stationary and migrated neutrophils were counted at (A) 2 and (B) 9 minutes after neutrophil 
flow stopped, and each expressed as a percentage of total adherent cells. Data are mean ± 
SEM, n=2. 
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Figure 11 – Comparison of the effect of TNFα and IL-1β on the rolling and migration 
velocities of neutrophils recruited to DMEC from flow. 
DMEC monocultures were stimulated with 100U/ml TNFα or 5x10-9 g/ml IL-1β for 4h before 
being exposed to a flow of neutrophils (1x106/ml) at a rate of 0.4ml/min for 4 minutes. (A) 
Rolling and (B) migration velocities were calculated as average values from ten rolling or 
transmigrated cells respectively, and expressed in µm/s (rolling) and µm/min (migration). 
Data are mean ± SEM, n=2. 
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3.3 The presence of hydrocortisone affects neutrophil recruitment to 
DMEC at low doses of TNFα 
Neutrophil adhesion to DMEC at 1U/ml and 10U/ml TNFα was lower than expected 
from historical data obtained with HUVEC. We subsequently identified hydrocortisone 
(HC) in the DMEC medium and hypothesised that its presence was responsible for 
our observations. To test this, we cultured DMEC in the presence or absence of HC 
and, as before, stimulated them with increasing doses of TNFα (0, 1, 10 and 
100U/ml) for 4h before the perfusion of neutrophils. Dose-dependent neutrophil 
recruitment was apparent once again (Figure 12), however much higher levels of 
adhesion were observed when DMEC were stimulated with 1 and 10U/ml TNFα in 
the absence of HC compared to those cultured in HC-containing medium (Figure 
13). In contrast to adhesion, HC presence had little effect on neutrophil behaviour. 
Low dose TNFα (1U/ml) supported more rolling and stationary neutrophils compared 
to 10 and 100U/ml, while significantly more migration was observed at 100U/ml 
compared to lower TNFα concentrations (Figure 14). Rolling velocity was also 
highest at 1U/ml (Figure 15). 
 
Taken together, the above results confirmed our hypothesis that hydrocortisone 
reduced neutrophil recruitment to DMEC at low TNFα doses. In view of this, all 
subsequent experiments were conducted in hydrocortisone-free media.  
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Figure 12 – Effect of TNFα concentration on neutrophil recruitment to DMEC from flow 
in hydrocortisone-free DMEC medium. 
DMEC monocultures in hydrocortisone-free DMEC medium were stimulated with TNFα for 4h 
before being exposed to a flow of neutrophils (1x106/ml) at a rate of 0.4ml/min for 4 minutes. 
The total number of adhering neutrophils was expressed as neutrophils/mm2/106 cells 
perfused and determined at 2 and 9 minutes after neutrophil flow stopped. Two-way ANOVA 
showed a significant effect of both TNFα concentration (P<0.0001) and time (P<0.05) on 
neutrophil adhesion. * = P<0.05 and *** = P<0.001 for comparison of 10U/ml and 100U/ml 
TNFα to unstimulated control (0U/ml TNFα) by Bonferroni post-tests. Data are mean ± SEM, 
n=3. 
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Figure 13 – Effect of hydrocortisone (HC) on neutrophil recruitment to TNFα-
stimulated DMEC from flow. 
DMEC monocultures in hydrocortisone-free or complete DMEC medium were stimulated with 
TNFα for 4h before being exposed to a flow of neutrophils (1x106/ml) at a rate of 0.4ml/min 
for 4 minutes. The total number of adhering neutrophils was expressed as 
neutrophils/mm2/106 cells perfused and determined at 2 minutes after neutrophil flow 
stopped. Two-way ANOVA showed a significant effect of both TNFα concentration and HC 
on neutrophil adhesion (P≤0.0001). *** = P<0.001 for the effect of HC at 10U/ml TNFα by 
Bonferroni post-test. Data are mean ± SEM, n=3.  
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Figure 14 – Effect of TNFα concentration on the behaviour of neutrophils recruited to 
DMEC from flow in hydrocortisone-free DMEC medium. 
DMEC monocultures in hydrocortisone-free DMEC medium were stimulated with TNFα for 4h 
before being exposed to a flow of neutrophils (1x106/ml) at a rate of 0.4ml/min for 4 minutes. 
Rolling, stationary and migrated neutrophils were counted at (A) 2 and (B) 9 minutes after 
neutrophil flow stopped, and each expressed as a percentage of total adherent cells. In A, 
two-way ANOVA showed a significant effect of neutrophil behaviour (P = 0.05), but not TNFα 
concentration, on % adherent neutrophils. * = P<0.05 and ** = P<0.01 by Bonferroni post-
tests. Data are mean ± SEM, n=3. 
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Figure 15 – Effect of TNFα concentration on the rolling and migration velocities of 
neutrophils recruited to DMEC from flow in hydrocortisone-free DMEC medium. 
DMEC monocultures in hydrocortisone-free DMEC medium were stimulated with TNFα for 4h 
before being exposed to a flow of neutrophils (1x106/ml) at a rate of 0.4ml/min for 4 minutes. 
(A) Rolling and (B) migration velocities were calculated as average values from ten rolling or 
transmigrated cells respectively, and expressed in µm/s (rolling) and µm/min (migration). 
Two-way ANOVA showed a significant effect of both TNFα concentration and neutrophil 
rolling and migration velocity (P < 0.05). Data are mean ± SEM, n=3.  
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3.4 MSC in co-culture with DMEC or HUVEC do not significantly reduce 
neutrophil adhesion 
Previously it has been shown that BMMSC in co-culture with HUVEC significantly 
reduced cytokine-induced neutrophil adhesion and transmigration compared to 
HUVEC monoculture (Luu et al. 2013). The effect on neutrophil adhesion was 
apparent at MSC:HUVEC ratio of 1:25, while reduction in transmigration was already 
seen at ratios of 1:500 and below (Luu et al. 2013). We wished to examine if the 
same happened with DMEC by directly comparing neutrophil recruitment to 
MSC:DMEC and MSC:HUVEC co-cultures. The two co-cultures, and their respective 
monocultures, were incubated with 100U/ml TNFα for 4h before neutrophils were 
perfused as before. In contrast to findings by Luu et al, DMEC and HUVEC co-
cultures with BMMSC did not have a significant impact on neutrophil adhesion levels 
compared to monocultures (Figure 16). Similarly, we did not observe an effect on 
neutrophil behaviour (Figure 17) or on the velocity of rolling or migrating cells 
(Figure 18). Of note, the calculated MSC:EC ratios were very variable between 
individual experiments, providing a possible explanation for lack of co-culture effect 
(Table 2). We also observed that the presence of BMMSC appeared to cause DMEC 
to retract or detach over the duration of the flow assay, leaving large gaps in the 
monolayer which were not evident in DMEC monoculture (Figure 19A). The same 
was not true for MSC:HUVEC co-cultures, which remained intact (Figure 19B).  
 
Overall, we concluded that the presence of BMMSC did not suppress neutrophil 
recruitment to DMEC or HUVEC, but that DMEC may not be suitable for MSC co-
culture studies due to their tendency to retract under flow. 
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Figure 16 – Effect of MSC:EC co-culture on neutrophil recruitment to TNFα-stimulated 
endothelium from flow. 
DMEC or HUVEC monocultures and their respective co-cultures with BMMSC were 
stimulated with 100U/ml TNFα for 4h before being exposed to a flow of neutrophils (1x106/ml) 
at a rate of 0.4ml/min for 4 minutes. The total number of adhering neutrophils was expressed 
as neutrophils/mm2/106 cells perfused and determined at 2 minutes after neutrophil flow 
stopped. Data are mean ± SEM, n=4. 
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Figure 17 – Effect of MSC:EC co-culture on the behaviour of neutrophils recruited to 
TNFα-stimulated endothelium from flow. 
(A) DMEC or (B) HUVEC monocultures and their respective co-cultures with BMMSC were 
stimulated with 100U/ml TNFα for 4h before being exposed to a flow of neutrophils (1x106/ml) 
at a rate of 0.4ml/min for 4 minutes. Rolling, stationary and migrated neutrophils were 
counted at 2 minutes after neutrophil flow stopped, and each expressed as a percentage of 
total adherent cells. Data are mean ± SEM, n=4. 
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Figure 18 – Effect of MSC:EC co-culture on the rolling and migration velocities of 
neutrophils recruited to TNFα-stimulated endothelium from flow. 
DMEC or HUVEC monocultures and their respective co-cultures with BMMSC were 
stimulated with 100U/ml TNFα for 4h before being exposed to a flow of neutrophils (1x106/ml) 
at a rate of 0.4ml/min for 4 minutes. (A) Rolling and (B) migration velocities were calculated 
as average values from ten rolling or transmigrated cells respectively, and expressed in µm/s 
(rolling) and µm/min (migration). Data are mean ± SEM, n=4. 
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Figure 19 – Effect of MSC incorporation into the endothelium on the EC monolayer. 
DMEC or HUVEC were seeded into ibidi channel slides such that they would yield a 
confluent monolayer within 24h. BMMSC labelled with Cell Tracker Green were then added 
to the same channel slides and allowed to incorporate for a further 24h. The co-cultures were 
treated with TNFα for 4h before being exposed to neutrophil flow. Following the flow-based 
adhesion assay, phase-contrast and fluorescent images were taken down the centre of each 
channel using x10 magnification. (A) Comparison of DMEC monoculture and MSC:DMEC 
co-culture during the same experiment, where BMMSC (fluorescent cells) caused DMEC to 
retract or detach over the course of the flow assay. (B) Comparison of MSC:DMEC and 
MSC:HUVEC co-culture during the same experiment, where BMMSC caused DMEC but not 
HUVEC to retract or detach over the course of the flow assay. Images representative of 4 
independent experiments, where DMEC were observed to retract in three out of the four 
experiments. 
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Table 2 - MSC:EC ratios obtained during co-culture of BMMSC with DMEC or HUVEC 
Experiment no. MSC:DMEC ratio MSC:HUVEC ratio 
1 1:25 1:40 
2 1:80 1:40 
3 1:14 1:8 
4 1:40 1:16 
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3.5 MSC phenotype may be affected by prolonged cytokine treatment 
Our collaborators have observed that synovial fibroblasts (SF) cultured in low-serum 
media upregulate their expression of GP38 upon prolonged stimulation with TNFα, 
and that of CD248 when exposed to TGFβ (Croft et al. n.d., unpublished data). Here 
we address two distinct questions. We examine whether there is an effect of low-
serum media on MSC surface marker expression. We also inspect whether similar 
changes occur in the phenotype of MSC when treated with cytokines for prolonged 
periods. We therefore stimulated BMMSC with TNFα or TGFβ for 4-6 days before 
analysing the expression of GP38, CD248 and MSC surface markers CD73 and 
CD90. This was done in both complete and low-serum media for comparison. 
 
BMMSC expressed both CD73 and CD90 in complete media, and this was 
unchanged in low-serum conditions. Prolonged cytokine treatment made a 
substantial difference to the expression of these markers only in the case of TGFβ 
stimulation in low-serum media. In this instance CD73 and CD90 expression was, 
though still positive, markedly reduced (Figure 20). The effect was especially 
pronounced for CD73. Therefore, while low-serum media alone did not impact on 
MSC marker expression, it did produce a notable change when coupled to TGFβ 
treatment, suggesting a role for this cytokine in altering the MSC phenotype. 
 
For assessment of GP38 expression we used lymphatic endothelial cells (LEC), 
which are known to express high levels of this protein, as positive control. Compared 
to LEC, none of the BMMSC under investigation expressed GP38 (Figure 21). The 
mean fluorescence intensities (MFI) were similarly low for all BMMSC treatment 
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groups, with no significant effect of serum deprivation or cytokine stimulation. To 
confirm this, the fluorescence emission spectra of serum-deprived cytokine-treated 
BMMSC were compared to those of untreated BMMSC (Figure 22). All of them 
overlapped and were in the negative fluorescence region. It was concluded, 
therefore, that BMMSC did not express GP38, and this remained unchanged with 
serum deprivation or cytokine treatment. 
 
Based on evidence suggesting that a subset of CD8+ T lymphocytes expresses 
CD248 (Watkins et al. 2009), we used freshly isolated peripheral blood lymphocytes 
(PBL) as our positive control for BMMSC CD248 expression. Labelling PBL with a 
FITC-conjugated anti-human CD8 antibody (BD Biosciences – Pharmingen, San 
Diego, California, USA) yielded a substantial CD8+ population, but CD248 expression 
could not be detected (Figure 23). This meant we had no positive control for our 
assay, rendering the interpretation of the results difficult. The only sample to show 
any shift in the direction of positive fluorescence compared to CD248-negative 
isotype control were the untreated BMMSC cultured in complete media (Figure 24). 
This suggests these cells could be expressing some CD248, although it is impossible 
to say for certain without a positive control. The MFI of all the other BMMSC subsets 
and PBL were comparatively lower (Figure 24). To confirm this difference in 
fluorescence, the emission spectra of serum-deprived cytokine-treated BMMSC were 
once again compared to those of untreated cells. They showed that any CD248 
expression that might have been present in untreated BMMSC was lost upon serum 
deprivation and cytokine treatment (Figure 25). 
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Overall, the effects of low-serum conditions and cytokine stimulation, or lack thereof, 
on BMMSC expression of CD73, CD90 and GP38 were clear. On the other hand, we 
were unable to draw any definite conclusions regarding CD248 expression by 
BMMSC due to lack of a positive control for this assay.  
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Figure 20 – CD73 and CD90 expression by BMMSC. 
BMMSC cultured in complete or low-serum media were either left untreated or treated with 
TNFα or TGFβ for 4-6 days. Upon completion of treatment, BMMSC were labelled with anti-
human CD73-FITC or anti-human CD90-Brilliant Violet™ 421 antibodies, and their 
fluorescence emission spectra for (A) CD73 and (B) CD90 examined by flow cytometry. Low 
cell numbers in the sample prevented use of negative isotype controls; however, the MSC 
flow cytometry protocol had been extensively employed before and was deemed reliable. 
Representative histograms from n=2. 
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Figure 21 – GP38 expression by BMMSC compared to lymphatic endothelial cells 
(LEC). 
BMMSC cultured in complete or low-serum (LS) media were either left untreated or treated 
with TNFα or TGFβ for 4-6 days. Upon completion of MSC treatment, LEC and BMMSC were 
labelled with anti-human GP38 antibody conjugated to PE dye and their fluorescence 
emission compared to that of negative isotype control. (A) Representative histogram of LEC 
showing positive fluorescence. (B) Mean fluorescence intensities (MFI) of BMMSC in 
complete or LS media compared to LEC. Data are mean ± SEM, n=3. 
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Figure 22 – GP38 expression by serum-deprived cytokine-treated BMMSC compared 
to untreated controls. 
BMMSC cultured in complete or LS media were either left untreated or treated with TNFα or 
TGFβ for 4-6 days. Upon completion of treatment, BMMSC were labelled with anti-human 
GP38 antibody conjugated to PE dye. Fluorescence emission for TNFα- and TGFβ-treated 
BMMSC in LS media was compared to those of untreated controls in both complete and LS 
media to obtain their (A) representative histograms showing negative fluorescence, (B) MFI 
and (C) % positive-fluorescing cells. Data are mean ± SEM, n=3.  
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Figure 23 – CD8 and CD248 expression by peripheral blood lymphocytes (PBL). 
PBL were labelled with anti-human CD8-FITC or anti-human CD248-FITC antibody. 
Fluorescence emission spectra were compared for PBL expression of (A) CD8 and (B) 
CD248, showing there was no overlap between CD8+ PBL and CD248 expression. 
Representative histograms from n=2. 
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Figure 24 – CD248 expression by BMMSC compared to PBL. 
BMMSC cultured in complete or LS media were either left untreated or treated with TNFα or 
TGFβ for 4-6 days. Upon completion of MSC treatment, PBL and BMMSC were labelled with 
anti-human CD248 antibody conjugated to FITC dye and their fluorescence emission 
compared to that of negative isotype control. (A) Representative histogram of untreated 
BMMSC in complete media. (B) MFI of BMMSC in complete or LS media compared to PBL. 
Data are mean ± SEM, n=3. 
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Figure 25 – CD248 expression by serum-deprived cytokine-treated BMMSC compared 
to untreated controls. 
BMMSC cultured in complete or LS media were either left untreated or treated with TNFα or 
TGFβ for 4-6 days. Upon completion of treatment, BMMSC were labelled with anti-human 
CD248 antibody conjugated to FITC dye. Fluorescence emission for TNFα- and TGFβ-
treated BMMSC in LS media was compared to those of untreated controls in both complete 
and LS media to obtain their (A) representative histograms, (B) MFI and (C) % positive-
fluorescing cells. Data are mean ± SEM, n=3.  
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4. DISCUSSION 
The immunomodulatory properties of MSC have been the subject of much research, 
but their ability to suppress neutrophil adhesion to inflamed endothelium has only 
been demonstrated recently (Luu et al. 2013) using macrovascular EC. In this project 
we sought to characterise neutrophil adhesion to the more physiologically relevant 
microvascular endothelium and examine whether it can be suppressed by MSC. We 
also studied how MSC phenotype may change in response to prolonged cytokine 
treatment, with a view to incorporating these altered cells into neutrophil adhesion 
assays in the future. We found that DMEC supported TNFα dose-dependent 
neutrophil recruitment, which was reduced in the presence of hydrocortisone at low 
doses of the cytokine. TNFα and IL-1β stimulation of DMEC resulted in comparable 
levels of neutrophil adhesion. We did not observe suppression of endothelial 
neutrophil recruitment in MSC:EC co-cultures, but we were able to show that MSC 
phenotype may change with cytokine treatment under low-serum conditions. 
Characterising these changes further, and how they may modulate neutrophil 
recruitment to vascular endothelium, could significantly expand our knowledge on 
MSC-EC crosstalk within a chronically inflamed environment. 
 
4.1 DMEC support neutrophil adhesion in the same way as HUVEC 
While neutrophil recruitment to cytokine-stimulated HUVEC has been extensively 
studied in the past (e.g. Bahra et al. 1998; Luu et al. 2003; Sheikh et al. 2005; Burton 
et al. 2011), only a handful of studies examined interactions between neutrophils and 
DMEC. They looked at either static adhesion of neutrophils to inflamed endothelium 
(Saalbach et al. 2000; Schmitz et al. 2011) or at routes of neutrophil transendothelial 
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migration (Marmon, Hinchey, et al. 2009; Marmon, Cammer, et al. 2009). None have 
examined neutrophil recruitment from flow. In addition, no studies have looked at 
MSC:DMEC co-culture or its impact on neutrophil adhesion before, making this 
project the first to address this gap in knowledge.  
 
We first examined and characterised neutrophil adhesion to DMEC monoculture from 
flow. The TNFα dose-dependence of neutrophil recruitment and the maximum 
adhesion levels were consistent with previous findings in HUVEC (e.g. Bahra et al. 
1998; Sheikh et al. 2005; Luu et al. 2013). However, the levels of adhesion at lower 
TNFα concentrations (1 and 10U/ml) were unexpectedly low at first, which was 
subsequently found to be due to the presence of hydrocortisone (HC) in DMEC 
medium. HC naturally exerted its anti-inflammatory effect and overwhelmed the effect 
of TNFα when the concentration of the latter was low enough. Once hydrocortisone 
was left out of the monoculture preparation, the levels of adhesion at low TNFα 
concentrations rose significantly to match those previously seen in HUVEC (e.g. 
Sheikh et al. 2005). We concluded that DMEC and HUVEC supported dose-
dependent neutrophil recruitment equally well. This similarity is supported by a study 
which found comparable levels of E-selectin expressed on both HUVEC and DMEC 
when they were exposed to inflammatory stimuli (Vora et al. 1996). 
 
Stimulation of the DMEC monolayer with high-dose IL-1β compared to high-dose 
TNFα did not show any significant differences in neutrophil adhesion levels, 
suggesting these two pro-inflammatory cytokines had much the same effect on 
microvascular endothelium. This was once again in keeping with previous findings in 
HUVEC, where both cytokines induced similar levels of neutrophil capture (Sheikh et 
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al. 2005). However, increases in shear stress have been shown to lead to a decrease 
in endothelial response to TNFα but not IL-1β (Sheikh et al. 2005; Luu et al. 2010); 
this would be worth investigating in DMEC in the future. 
 
Neutrophil behaviour upon adhering to DMEC monoculture was comparable to 
previous observations in HUVEC, where increases in TNFα concentration led to 
decreases in rolling and firm adhesion and increases in transendothelial migration of 
neutrophils (Bahra et al. 1998; Luu et al. 1999; Luu et al. 2000). The kinetics of 
migration, however, were not significantly affected by increasing TNFα concentration, 
once again making DMEC comparable with HUVEC (Luu et al. 1999). Even the 
migration velocities supported by the two endothelia were both found to be in the 
region of 14µm/min (Luu et al. 2003). Consistent with the above observations that 
TNFα and IL-1β induced much the same neutrophil adhesion levels, the behaviour 
seen for the two cytokines was largely similar as well. 
 
The above findings suggested that DMEC were a suitable EC model to take forward 
in our studies, supporting largely the same neutrophil adhesion and behaviour as 
HUVEC. In view of the fact that hydrocortisone was clearly able to reduce the effect 
of low-dose TNFα on neutrophil adhesion to DMEC, it was decided to move onto 
MSC:EC studies using hydrocortisone-free media. Our interest in the potential of 
MSC to suppress endothelial neutrophil recruitment meant that any presence of 
hydrocortisone could ‘mask’ the immunosuppressive effect of MSC. 
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4.2 MSC:EC co-culture does not show immunosuppressive effects 
The only study to have examined MSC modulation of neutrophil recruitment to 
HUVEC (Luu et al. 2013) found that MSC:HUVEC co-culture was capable of down-
regulating neutrophil adhesion and transmigration compared to HUVEC monoculture. 
We applied the same methods used by Luu et al. to study neutrophil adhesion to 
MSC:DMEC and MSC:HUVEC co-cultures in parallel, comparing them to their 
respective monocultures and to each other. In contrast to findings from the study 
above, we did not observe any effects of MSC co-culture with DMEC or HUVEC on 
neutrophil adhesion, behaviour or migration kinetics. Since this was the first study of 
its kind to be performed, and there is a general lack of relevant literature on MSC:EC 
co-cultures – particularly in the case of DMEC – it is difficult to interpret the lack of 
immunosuppression in this instance. MSC have previously shown a tendency 
towards differentiation when in co-culture with DMEC (Laranjeira et al. 2012), 
although this is unlikely to have happened in such a short time span. It is possible 
that using a different batch of BMMSC to that utilised in the study by Luu et al. 
decreased the suppressive effect on neutrophil adhesion and transmigration, such 
that it would not be seen in n=4. Consequently, increasing the number of experiment 
repeats may highlight a difference in neutrophil recruitment between DMEC and 
HUVEC mono- and co-cultures. 
 
It is important to note that MSC:EC ratios were very variable between experiments, 
unlike those obtained by Luu et al. This was most likely due to the large gaps 
apparent in DMEC:MSC co-culture where DMEC had either retracted or detached, 
thus rendering the calculation of ratios difficult. The gaps were mostly around the 
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areas of MSC integration into the monolayer, and it is likely this happened during or 
just after the flow assays, when the cells coming off could have been carried away by 
the flow. The fact that such gaps were not seen in DMEC monocultures or in HUVEC 
mono- or co-cultures would suggest that DMEC are not suitable for supporting 
integration of MSC in vitro. HUVEC did not detach or retract like DMEC did, although 
here too the variable ratios were apparent. This may be explained by the varying 
confluence of the monolayers at the point of the assay. It was not always easy to 
evaluate how confluent the HUVEC culture flasks were before the cells were 
resuspended and seeded, therefore possibly resulting in channels where the EC 
population was too dense. 
 
4.3 MSC surface marker expression changes with cytokine treatment 
MSC and fibroblasts have been shown to be closely related, both exhibiting 
differentiation potential and expression of MSC surface markers such as CD73 and 
CD90 (Haniffa et al. 2009; Alt et al. 2011). Our collaborators recently demonstrated 
that synovial fibroblasts cultured in low-serum conditions were able to adopt a pro-
inflammatory (GP38+) or regulatory (CD248+) phenotype, depending on their 
stimulation with TNFα or TGFβ respectively (Croft et al. n.d., unpublished data). We 
therefore wished to characterise potential changes in MSC phenotype under serum 
deprivation and after prolonged cytokine stimulation. 
 
Our results clearly showed that BMMSC, unlike fibroblasts, did not express GP38 
under any of the conditions tested, suggesting they had not adopted a more pro-
inflammatory phenotype. This seemed consistent with previous findings that the 
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presence of pro-inflammatory cytokines such as TNFα ‘primed’ the MSC towards 
immunosuppression and tissue regeneration rather than immune stimulation (e.g. 
Ren et al. 2008; Prasanna et al. 2010; Kemp et al. 2010; Hemeda et al. 2010). These 
studies, however, examined the effects of MSC on lymphocyte proliferation rather 
than neutrophil recruitment, and in almost all cases required the additional presence 
of interferon-gamma (IFNγ) to lead to correct MSC priming (Prasanna et al. 2010; 
Hemeda et al. 2010; Ren et al. 2008; Krampera et al. 2006). We have not yet looked 
at the potential of serum-deprived, cytokine-stimulated MSC to modulate neutrophil 
recruitment, but future studies of this kind may reveal interesting immunomodulatory 
effects. 
 
We were not able to draw definite conclusions about MSC expression of CD248, but 
the obvious decrease in CD73 and CD90 expression after treatment with TGFβ in 
low-serum conditions is interesting. A previous study reported that in vitro angiogenic 
stimuli combined with low-serum conditions led to the appearance of a CD90-
negative MSC subset, which had high proliferative potential and increased propensity 
towards osteogenic and adipogenic differentiation (Campioni et al. 2008). It is entirely 
possible that TGFβ with low-serum media started inducing MSC differentiation in our 
study. Interestingly, a direct involvement of CD90 in neutrophil binding to activated 
DMEC and fibroblasts has been previously reported (Saalbach et al. 2000). Exploring 
what happens to CD73 and CD90 expression after longer periods of MSC cytokine 
stimulation (7-14 days), and whether this may lead to suppression of neutrophil 
recruitment to DMEC, could therefore be of interest. 
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4.4 Future studies 
In light of the observed changes in CD73 and CD90 expression, further studies of 
how expression of these and other MSC surface markers (e.g. CD44, CD105) may 
change under serum deprivation and prolonged cytokine treatment would be 
interesting. Assaying supernatants from long-term cultures of MSC under the above 
conditions would reveal if they secrete any immunomodulatory soluble factors, such 
as IL-6, IDO or iNOS (Waterman et al. 2010). Subsequent incorporation of these 
MSC into co-culture with DMEC and HUVEC could give us valuable insights into their 
capability to modulate endothelial neutrophil recruitment from flow depending on 
changes in MSC phenotype. Obtaining consistent MSC:EC ratios across experiments 
would be crucial for successful data interpretation. Finally, in order to mimic the in 
vivo stromal microenvironment more faithfully, examining the immunosuppressive 
effects of co-culture when MSC and EC are seeded on opposite sides of a Transwell 
filter (McGettrick et al. 2009) or in 3D culture constructs (Jeffery et al. 2013) rather 
than incorporated into endothelial monolayers would be of value. 
 
4.5 Conclusion 
We used a well-established flow-based adhesion assay model to show that 
neutrophil recruitment is equally well supported by DMEC as it is by HUVEC. We 
were not able to replicate the neutrophil recruitment suppression previously seen in 
MSC:HUVEC co-culture, which could have been due to technical difficulties 
encountered during the experiment. However, we showed that MSC phenotype may 
change during prolonged cytokine stimulation. Further studies of this phenomenon, 
as well as how it may impact neutrophil adhesion in MSC:EC co-culture, are needed 
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to better understand the interactions that may take place between these cells in 
inflammatory environments. 
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